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Abstract 
If you can look into the seeds of time,  
And say which grain will grow and which will not. 
- Macbeth. Act I, Scene 3. 
Knowledge of the three dimensional structure of a protein provides insight into its 
mechanism, as well as into potential sites for drug targeting.  Often these insights provide 
functional information about an unknown protein, lead to a deeper understanding of how 
damaged proteins cause disease, and potentially reveal a path to new drug treatments.  The most 
common method to determine protein structure and function is to crystallize them and probe 
them with X-rays to determine their structure.   Protein crystallization still remains an art rather 
than an exact science, and it is extremely difficult to predict the conditions that will ultimately 
result in crystals resulting in difficulties in structure determination.  Recent efforts in structural 
biology have helped to lessen bottlenecks using robotics and/or microfluidics, leading to 
improved, and often automated, high throughput methodologies for screening, crystallization, 
and X-ray diffraction analysis of novel protein targets.  Even with these improvements, the 
harvesting and mounting of protein crystals for X-ray analysis remains a cumbersome, manual 
step in the structural biology pipeline that especially hampers collection of data from 
small/fragile crystals.  
Obtaining high-quality protein crystals is the main obstacle for structure elucidation because 
crystallization is a complex, multi-parametric process that involves setting up thousands of 
crystallization trials to screen a vast chemical space. Current data collection strategies involve 
harvesting a single crystal from the crystallization droplet in which it was grown, a process that 
often damages the crystal, followed by cryocooling the crystal, before subjecting it to 
monochromatic X-rays to elucidate the structure from X-ray data. For de novo structure 
determination, phase information also needs to be collected to convert diffraction data (that 
records intensities) to structural information.  Phase information is most commonly obtained 
experimentally by measuring anomalous diffraction signal.  The collection of high quality 
phasing data is dependent on having diffraction data with a high signal-to-noise ratio while 
minimizing radiation-induced damage and crystal non-isomorphism.   
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The microfluidic crystallization platform developed in this work  serves to overcome issues 
with current methods in protein structure determination. Specifically, it allows for screening 
(crystallization) conditions together with on-chip X-ray analysis of crystals formed, and can be 
further used for relevant functional studies of proteins via time resolved crystallography. 
Furthermore, this is the first example of a microfluidic chip being used for room temperature 
phasing from diffraction data collected and merged from multiple crystals.   
Microfluidics offers more precise control over the composition and the kinetics of a 
crystallization trial than what is possible using conventional methods such as vapor diffusion and 
microbatch.  The ability to control fluid flow and transport at such a small preparative scale 
makes it an ideal platform for crystallization since microfluidic devices use minimal amounts of 
protein solution, which are often times not available in large quantities for medically relevant 
human targets.  The use of appropriate polymers in chip fabrication enables on-chip analysis thus 
eliminating the need for crystal harvesting prior to analysis.  Identification of these materials and 
development of protocols to fabricate X-ray compatible microfluidic platforms is discussed in 
Chapter 2.  Proof-of-principle studies using model systems that validate the microfluidic chip 
and an alternate data collection strategy for merging datasets from multiple crystals is covered in 
Chapter 3.  Screening of conditions and de novo structure determination via on-chip collection of 
phase information is discussed in further detail in Chapter 4.  In Chapter 5, the application of 
microfluidic platforms for use in seeding studies is discussed.  Seeding is a method to improve 
chances of obtaining high quality crystals by separating the nucleation and growth phases in a 
crystallization trial, and this chapter focusses on how it was achieved using a microfluidic 
platform.   
Laue crystallography allows us to look at protein molecules in motion, helping us understand 
the complex pathways and structural changes that accompany protein function.  Chapter 6 
describes how X-ray transparent microfluidic chips can be used for collecting time resolved Laue 
data thus enabling functional studies on protein targets that would be cumbersome using 
traditional methods.  The platform developed here can also be used to enable structural studies 
that shed light on the change in structure during protein function, ranging from proteins that 
respond to stimuli such as light, pH, or the presence of ligands, to those that respond to 
temperature changes, thus allowing an unprecedented opportunity for a range of previously 
elusive biological studies. 
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Chapter 1 
Introduction 
Proteins are a large class of complex organic molecules that are essential for life.  They are 
fundamental components of all living cells and include many substances such as enzymes, 
hormones and antibodies.  Proteins play a central role in biological processes and are the true 
workhouses of all living systems. They play an essential role in growth and repair of body 
tissues, material transport, cell-cell signaling, energy storage and transduction, immune response 
and interaction between intra and extra cellular environment; in essence they participate in 
virtually every process within cells.  Many proteins catalyze reactions as enzymes, and are vital 
to metabolism.  They can also have structural or mechanical functions such as proteins in the 
cytoskeleton, a form of scaffolding that maintains cell shape.   
Proteins consist of one or more long chains of amino acids which are linked through peptide 
bonds and are maintained in distinct and varied 3-dimensional structures.  They fold into 
structural units consisting of alpha helices, beta sheets and other folded shapes with structural 
integrity being provided by chemical bonding between these structures (Figure 1).  These folded 
shapes and structural units are immensely important because they define the protein's function in 
the cell.  Some protein shapes fit perfectly in cell receptors, turning chemical processes on and 
off, like a key in a lock; whereas others work to transport molecules (e.g., oxygen, nutrients) 
throughout the body (e.g., hemoglobin's shape is ideal for carrying oxygen).  When proteins fail 
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to take on their preordained shapes, there can be serious consequences: misfolded proteins have  
been implicated in diseases such as Alzheimer's, mad cow, and Parkinson's, among others.  
Proteins can be informally divided into three main classes, which correlate with typical tertiary 
structures: globular (soluble) proteins, fibrous proteins, and membrane proteins.  Almost all 
globular proteins are soluble and many are enzymes.  Fibrous proteins are often structural, such 
as collagen, the major component of connective tissue, or keratin, the protein component of hair 
and nails.  Membrane proteins often serve as receptors or provide channels for polar or charged 
molecules to pass through the cell membrane.
1
  In this dissertation, I will mainly focus on soluble 
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and membrane proteins.  In terms of structure determination, soluble proteins are easier to 
crystallize than membrane proteins, which are way underrepresented in the Protein Data Bank 
(PDB). 
Gaining a fundamental understanding into these complex structures and how proteins are 
able to fold into their requisite shapes is still poorly understood and remains a central question in 
biochemistry.  To understand protein function we need to know their structure and this is the 
ultimate aim of the work presented here. 
1.1 Protein crystallization 
The three dimensional structure of a protein determines how it functions and interacts with 
other molecules.  To fully understand these processes, pathways and eventually how organisms 
function, researchers need to know the structure of the protein.  Whereas genomics can reveal the 
sequence of amino acids in a protein, structural biology tells us how that sequence folds up into a 
particular shape
2
.  The different functions of the protein molecule and its interaction with other 
molecules are determined by its three dimensional structure.  The human proteome is estimated 
to contain at least a million proteins, so in order to map out the functionality of all the proteins an 
efficient, high throughput technological effort is required to determine structural information for 
all human proteins.
3
  The Protein Structure Initiative (PSI) was launched by the National Institute 
of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH) in 2000 
with the aim of obtaining high resolution structures of 10000 proteins in a decade
4
.  To achieve 
this goal, the PSI also focused on the development of innovative approaches and tools that 
streamline and speed many steps involved in generating protein structures, and to incorporate 
these new methods into process pipelines that turn DNA sequence information into protein 
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structures.  Figure 2 shows the rapid development achieved by the PSI in solving and depositing  
structures of proteins, while highlighting the difficulty in obtaining membrane protein 
structures
5
.  Similar to this, the Membrane Protein Initiative Roadmap has been instrumental in 
driving research for structure determination of membrane proteins. 
Protein structures are considered to contain a treasure trove of information about life's 
molecular machines.  The use of X-ray crystallography, nuclear magnetic resonance 
spectroscopy and cryo-electron microscopy reveal structural information which provides insight 
into how these complex machines operate.  Often these insights can help to discover the likely 
function of an unknown protein, lead to a deeper understanding of how misshaped proteins cause 
disease, and potentially reveal a path to new drug treatments
2
.  
Protein crystallography is an important aspect of structural biology that provides information 
on the three dimensional structure of proteins and insight into their function.  This intensive, 
multi-step process includes expression, purification, and crystallization of protein material, 
followed by harvesting of the crystals for X-ray analysis (Figure 3).  Some of these steps have 
been improved recently, but major bottlenecks still exist in identifying crystallization conditions 
with limited material available and in avoiding crystal damage while manually harvesting the 
oftentimes small, delicate crystals for X-ray analysis
6
. 
Current methods in crystallography rely on a single protein crystal to give the entire 
structural data at cryogenic temperatures to avoid radiation damage
7
.  This requires physically 
harvesting individual crystals from crystallization droplets.  The manual handling, exposure to 
the environment during harvesting and cryo-cooling has the potential to lead to degradation of 
the crystal thereby affecting the quality of data collected.  As a result of these issues, researchers 
try to find alternative crystallization conditions yielding more robust crystals of the same protein 
6 
 
or the protein is abandoned in favor 
of crystallization of other, hopefully 
more robust proteins.   
 
Structural data from a protein crystal 
needs to be coupled with phase 
information which can be obtained 
experimentally through methods like 
single wavelength anomalous 
diffraction (SAD) or multi-
wavelength anomalous diffraction 
(MAD), or through computational 
methods like molecular replacement
8
.  
For de novo structure determination, 
experimental methods are more useful 
since homologous structures of novel 
targets, as needed for molecular 
replacement, may not be readily 
available.   
While the success of structural 
biology efforts has been limited by 
bottlenecks associated with protein 
expression,
9-14
 purification,
6,14
 and 
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crystallization,
15-21
 the development of high throughput strategies utilizing robotics
4,16,22-25
 and 
microfluidics
17,26-76
 have helped to overcome some of these challenges.  Automated methods
21,73
 
also exist for the screening and collection of X-ray diffraction data from protein crystals.  
Despite this level of automation, the harvesting and mounting of crystals for X-ray 
analysis
22,65,67,70,77
   remains the only fully manual step in the structural biology pipeline.  
Once the protein has been expressed and purified satisfactorily, the next and most crucial 
step to obtaining structural information about the protein is growing diffraction quality crystals. 
However, methods for predicting protein crystallization conditions a priori have do not exist, so 
obtaining high quality crystals involves searching a vast multidimensional chemical space which 
could involve screening thousands of different precipitants, buffers, salts etc. in separate 
crystallization trials.
70,71,78-80
  Traditional vapor diffusion
18,19,81-84
 and microbatch
24,85,86
 methods 
continue to be the most commonly used crystallization techniques. However for sparse matrix 
screening a sizeable quantity of protein solution is required which is not always feasible in the 
initial stages of protein crystallization because of either difficulty in the expression or 
purification of a hitherto unknown protein.  Scalability is also an issue with current platforms.  
Hence technology that could screen hundreds of conditions using minimal amount of protein 
solution would significantly benefit the field.  
Once optimal crystallization conditions have been identified, traditional methods in X-ray 
crystallography require manual harvesting of the crystal from the crystallization chamber, cryo-
freezing the crystal, and mounting of the crystal onto a loop.  Handling of crystals can be 
particularly challenging if the crystals are small and fragile and can also lead to damage of the 
crystal due to handling and environmental shock that can occur when the crystal is retrieved 
from the environs in which it was grown.
36,82
  In case of many hard to crystallize proteins, micro 
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crystals can be grown, but mounting and collecting data from such crystals presents a challenge.  
Advances in synchrotrons have led to the development of micro beams which can obtain 
structural information from such crystals, but harvesting and mounting these tiny crystals 
manually is in extremely challenging.  A crystallization platform which enables in situ analysis 
would allow collecting slices of data from many such micro crystals and merging them to get a 
complete dataset.  Removal of this final, manual step of harvesting and ability to perform in situ 
analysis will open up the possibility of getting structural information from recalcitrant protein 
targets.  
1.2 Conventional methods for protein crystallization 
Determining the three dimensional structure of a protein involves many steps, starting from 
cloning, expression and purification of the protein, followed by crystallization and then 
collection of diffraction data.  Even when high quality, protein solution is available in plenty, 
producing diffraction quality crystals is the bottleneck of the protein structure determination 
pipeline.  My work is focused on developing tools to accelerate and simplify the crystallization 
process and make the data collection process easier.  To justify the methods and tools I am going 
to be using, I will first describe the methods which are most prevalent today for protein 
crystallization.  
There are two phases in growing high quality protein crystals for collecting X-ray diffraction 
data.  These are (a) the screening of a large number of chemical, biochemical and physical 
conditions that yield crystalline material, and (b) the systematic adjustment of these conditions to 
obtain crystals of high enough quality to collect diffraction data and pursue subsequent analysis.  
During screening, we may or may not get good quality crystals, but even if we get a shower of 
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microcrystals, that gives us some idea as to what the likely crystallization condition could be, 
and we move to the second step, i.e., optimization.  Every component in the crystallization  
 
cocktail (precipitant, salt, buffer, temperature, pH etc.) might have an impact on the final quality 
of the crystal.  Hence each of these parameters needs to be fine-tuned during the optimization 
step in order to get diffraction quality crystals.  Another way of optimization is to influence and 
control the very environment in which crystallization is taking place, for example by seeding, 
and this will be discussed later. 
When the objective is to grow protein crystals, a solution of the protein must be transformed 
or brought into a supersaturated state, whereby its return to equilibrium forces exclusion of 
protein molecules into the crystal.  If, from a saturated solution, for example, solvent is gradually 
10 
 
withdrawn by evaporation, temperature is lowered or raised appropriately, the pH is altered, or 
additives change the solvent concentration, or some other property of the system is altered, then 
the solubility limit may be exceeded and the solution will become supersaturated.  If a solid 
phase is present, or introduced, then strict saturation will be reestablished as protein molecules 
leave the solvent, join the solid phase (crystal), and equilibrium of the system is regained.
82
  If no 
solid (nuclei, previous protein crystal) is present as conditions are changed, then solute will not 
immediately partition into two phases.  The solid state does not necessarily develop 
spontaneously as the saturation limit is exceeded because energy, analogous to the activation 
energy of a chemical reaction, is required to create the second phase, the stable nucleus of a 
crystal or a precipitate.  A kinetic, or energy barrier has to be crossed to go further and further 
from equilibrium, into the zone of supersaturation.  On a phase diagram, (Figure 4), the line 
indicative of saturation is also a boundary that marks the requirement for energy-requiring events 
to occur in order for a second phase (ordered nucleus of a crystal) to be established, or the 
nonspecific aggregate that characterizes a precipitate.  Once a stable nucleus has formed in a 
supersaturated solution, it will continue to grow until the system regains equilibrium.  So long as 
non-equilibrium forces prevail and some degree of supersaturation exists to drive events, a 
crystal will grow or precipitate will continue to form.   
There are three main zones in the phase diagram (Figure 4): undersaturated, saturated and 
supersaturated.  The area under the solubility curve is the undersaturated region where 
spontaneous nucleation cannot occur and any crystal placed in this region will dissolve.  The 
next region, which is the saturated region, is defined by the experimentally defined solubility 
curve.  Along this curve, spontaneous nucleation will not occur, neither will crystals dissolve nor 
increase in size.  The supersaturated region above the solubility curve is divided into three 
11 
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further regions, the metastable zone, nucleation zone and precipitation zone.  The metastable 
zone which is directly next to the solubility curve is where nucleation will not occur, but crystals  
present in this zone will grow in size.  The second region, the nucleation zone, is where 
spontaneous homogenous nucleation can occur and crystals added to this solution will grow in 
size.  The final zone is the precipitation zone, which is extremely supersaturated with respect to 
crystal growth and will lead to amorphous precipitation.   
All methods of crystallization involve a phase transition, in which the protein is in the 
solution at the start of the experiment, and is forced to come out of solution and form crystals as 
the experiment progresses and the solution is driven towards supersaturation.  There are many 
methods used for bringing the protein solution into a supersaturated state, amongst them the most 
common ones are (a) microbatch, (b) vapor diffusion, (c) free interface diffusion and (d) dialysis. 
1.2.1 Microbatch crystallization 
Microbatch method
24,85,87,88
 is a scaled down method of batch crystallization method, where 
the protein and crystallizing agents are mixed at the final concentration into a droplet at the start 
of the experiment.  Supersaturation is achieved on mixing and conditions in the droplet change 
only when the protein leaves the solution to form crystals.  In microbatch experiments (Figure 
5a) crystallization trials are dispensed and incubated under low-density paraffin oil (0.87 g/ml)
88
. 
The aqueous crystallization drops are denser than the oil, so they remain immersed, where they 
are protected from evaporation, contamination and shock, thus making the plates more easily 
transportable.  The fundamental difference between diffusion based methods (vapor diffusion, 
FID) and microbatch is that diffusion based systems are dynamic in which conditions change 
throughout the crystallization process, whereas in microbatch, the samples are mixed at their 
final concentration at the start of the experiment; thus, conditions are constant within a normal 
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time frame of a crystallization experiment (1–3 weeks).  Thus microbatch experiments do not 
generally span as large a chemical space as is possible with diffusion based experiments.  A large 
number of microbatch experiments need to be set up to cover a range of conditions (in a phase 
diagram) that can be covered with a single vapor diffusion trial.  However, there are usually no 
changes in drop volume or pH, and crystals do not usually dissolve.   
Robotic systems can dispense nanoliter sized droplets for setting up hundreds of microbatch 
trials under oil.  Depending on the type of oil used
88,89
 microbatch technique can be used for 
screening as well as optimization.  It is compatible with almost all known precipitants, buffers 
salts and additives, with the exception of small molecule organic volatiles (phenol or dioxane) as 
these dissolve in the oil. 
1.2.2 Vapor diffusion 
Vapor diffusion
87,88,90
 is the most commonly used method for protein crystallization.  In this 
setup, a drop containing the protein solution and precipitant (at a lower concentration than what 
is needed for crystal formation) is equilibrated against a reservoir solution.  The precipitant and 
protein in the droplet gets concentrated over time due to dehydration-driven reduction of solution 
volume caused by equilibration of water vapor from the protein-containing droplet to a more 
hygroscopic reservoir solution.  During the crystallization process (see phase diagram in Figure 
4), the droplet passes through a range of conditions, thereby undergoing a self-screening process.  
Vapor diffusion trials can be set up as a hanging drop or a sitting drop trial (Figure 5b). 
Trials are usually conducted in 24-well plates (for example, Hampton Research or Molecular 
Dimensions), where each well is filled with 0.5–1 ml of reservoir solution and sealed with a 
siliconized glass or plastic coverslip. The wells are fitted with a support for the sitting drop, and 
14 
 
in the case of hanging drop; the crystallization droplets are pipetted onto the coverslip and 
inverted on to the reservoir well. 
There are instances when vapor diffusion is not an ideal method
88
 because of a number of 
problems.  These include (i) uncontrollable changes in drop volume and lack of control over 
exact droplet composition during crystallization, (ii) changes in pH due to volatile ions and (iii) 
changes in temperature that can cause dissolution of crystals.  In addition, the trials are not easily 
transportable, and as compared to microbatch trials a large amount of both protein and 
precipitant are required. 
1.2.3 Free interface diffusion 
Free interface diffusion (FID)
33,82,88
 is a relatively new technique where the protein and the 
precipitant are juxtaposed in a microchannel or capillary.   Due to diffusion over time, a 
concentration gradient develops in the system, and the system self-selects the optimum 
nucleation and growth conditions.  This technique is most powerful when suitable precipitant(s), 
additive(s), pH, and buffers are already known and tested, that is, as a fine-tuning screening and 
optimization technique.  Recently, several alternatives have been developed that has led to 
further exploration of this technique as a screening and structure determination tool.  An initial 
screening version using the method has been developed
65
, as a crystallization cassette in which 
multiple capillaries are simultaneously filled with the protein solution and then come into contact 
each with a different precipitant solution well and thus combines screening and optimization.  
FID based crystallization techniques have also been widely used in development of microfluidic 
chips for high throughput crystallization screening and the advantages of using microfluidics for 
implanting this technique are discussed later. 
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1.2.4 Dialysis 
In the dialysis
88,90
 method, the protein is sequestered from the precipitant solution by a 
semipermeable membrane that allows the precipitant solution to slowly mix with the protein  
 
molecules (which cannot cross the membrane). Dialysis provides an altered route across the 
phase diagram (Figure 5c) but requires expertise to set up.  In this method, solution composition 
is altered by diffusion of low molecular weight components through a semipermeable membrane. 
The ability to change the protein solution composition accurately any number of times and with 
small incremental changes makes this one of the more versatile crystallization methods.  Dialysis 
is also uniquely suited to crystallizations at low ionic strength, an approach shown to succeed in 
nearly 10% of all cases.
91
  It is also a convenient method for crystallization in the presence of 
volatile reagents such as alcohols. 
1.2.5 Seeding 
From the phase diagram of crystallization it is clear that the optimal conditions for nucleation 
and growth differ.  Therefore a method which can separate these two phenomena and can 
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optimize them independent of one another is particularly appealing.  Seeding is a one such 
technique where crystals are transferred from conditions that support only nucleation to those 
which support crystal growth
92,93
.  There are two basic seeding methods, macroseeding and 
microseeding.  In macroseeding a whole crystal is transferred from a condition where nucleation 
occurs to an area of lower supersaturation that supports growth.  In contrast, in microseeding, 
nuclei of crystals are added to the crystallization droplet at a growth inducing supersaturation.  
These nuclei are prepared by crushing crystals and preparing dilution series with different 
number of nuclei present in each series for further optimization.  Figure 6 shows examples of 
protein crystals grown via seeding.  A more detailed description of the seeding process is present 
in Chapter 5. 
1.2.6 The “ideal” crystallization platform 
All the approaches described above for protein crystallization have limitations.  Most of them 
require large amounts of proteins, which is often times hard to obtain for membrane proteins, or 
targets that are difficult to purify, especially when screening and optimization for a novel protein.  
There have been developments especially in robotics
16
 that allows for using nanoliter amounts of 
protein solution, but these methods require expensive and complicated ancillaries and robotic 
systems, which are often times out of reach for most biochemical laboratories.  A low-cost, 
simple to use, technology that uses minimal quantities of protein and reagents can prove to be a 
disruptive innovation in the protein crystallization community, which still uses plastic well-plates 
for setting up majority of the trials.  Microfluidics can also eliminate crystal harvesting and 
looping, which tends to damage fragile crystals or proves difficult in the case of tiny crystals, by 
allowing for on-chip crystal analysis through the use of suitable materials for chip fabrication.  
Also, traditional methods rely on collecting all data from a single cryo-cooled crystal, which 
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doesn’t allow the study of those proteins that are not amenable to cryo-crystallography or when 
the structure and function is desired to be studied at biologically relevant temperatures.  
Based on the above discussed issues in the current approach to perform X-ray 
crystallography on protein crystals, the attributes of an ideal crystallization platform can be 
enumerated as follows: 
1. Ability to screen multiple conditions, in high throughput fashion for protein 
crystallization 
2. Requirement of minimal amount of protein solution for crystallization trials 
3. Capability of on-chip analysis (eliminating manual harvesting, cryocooling and handling) 
4. Capability of room temperature data collection from multiple crystals 
5. Interfacing with current infrastructure at beamlines in synchrotrons 
Microfluidics has the capability of manipulating fluids on a very small scale ranging from 
microliters down to picoliters, and this has been used for a variety of applications ranging from 
chemical synthesis to biological studies.
94
  The ability to control fluid flow at such a small scale 
makes it an ideal platform for crystallization since microfluidic devices use minimal amounts of 
protein and precipitant which need to be mixed by free interface diffusion (FID) or counter 
diffusion in order for crystals to grow.  Ease of scaling out of microfluidic systems will enable 
setting up screens of hundreds of crystallization conditions while maintaining control over the 
conditions in each individual trial.  Traditional microfluidic chips are usually made out of 
materials which are not suited for on-chip analysis, which is discussed in further detail in the 
Chapter 2.  To overcome this issue, I use a material which is compatible with in situ X-ray 
analysis and also convenient for fabrication of microfluidic chips.  The material selection and 
subsequent design and fabrication of an X-ray compatible microfluidic device is one of the main 
focus areas of my research.  As discussed earlier, diffraction quality crystals of some novel 
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proteins have been challenging to grow, but showers of micro crystals which are individually too 
small to solve a structure completely have been grown.  Since microfluidics offers such precise  
 
fluid control and handling at a small, micro crystals of difficult proteins can easily be grown 
once the crystallization condition is known, and subsequently the protein structure can be 
obtained by collecting multiple datasets from many crystals and merging them together.  In 
summary, with its small scale, microfluidics addresses the current problems in protein 
crystallization in two ways: firstly, by allowing experiments to be carried out on novel proteins 
which are not available in large amounts and secondly, by enabling us to perform experiments 
which are difficult to implement on a large scale.  In addition to these scale advantages, the use 
of innovative materials that are transparent to X-rays in the chip fabrication would allow on-chip 
diffraction data collection, and thus remove manual handling of fragile protein crystals for the 
structure determination process. 
19 
 
1.3 Microfluidic platforms for protein crystallization 
In the same way in which integrated circuits brought about many technical advances in the 
electronics and computation industry, the ability of microfluidics to integrate multiple laboratory 
functionalities on a single chip significantly impact the field of chemical synthesis and biological 
studies. This ability of integration of massively parallel operations on a single chip has not only 
the potential to increase the speed and reliability of many conventional processes, but also bring 
down the cost of manufacturing and operation due to economies of scale. Microfluidics has been 
gaining popularity in structural biology, and has shown promise in many related fields ranging 
from studying protein folding with time resolved studies to growing high quality protein crystals 
for structure determination 
56,70,95,96
. 
Microfluidics devices for protein crystallization can be categorized into three main 
categories, 
(i) devices with active valves  (ii) droplet based devices and (iii) systems based on mimicking 
well plates, e.g. SlipChip.
80
  All these systems deal with nanoliters volumes of protein and 
precipitant solution but differ in the way of operation and use and in terms of the materials used 
for fabrication of the chip itself.  
In microfluidic systems of the first type, valves control the fluid flow of the solutions on the 
device.  The most prevalent valves in microfluidics are based on pneumatic actuation and can be 
broadly classified as (i) actuate-to-open
94,97
 (Figure 7a) and (ii) actuate-to-close
98
 (Figure 7b).  
Typically, the actuation of pneumatic microfluidic valves is based on the actuation of a thin 
membrane by pressurized air in a control layer that is positioned over a network of 
microchannels embedded in a fluid layer.  Actuate-to-close valves are operated by applying a 
positive pressure to collapse the membrane over the fluid layer into the fluid channel and thus  
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closing the channel, and need rounded fluid channels for the membrane to completely stop the 
flow or drive fluid out of the fluid chamber.  This effect is similar to pressing down on a ketchup 
packet and the ketchup squirting out from the mouth of the packet.  When the valves are not  
actuated, these valves are open, so transporting these chips from the fluid handling station to the 
X-ray chamber can lead to unwanted mixing between the various chambers.  Microfluidic 
systems based on these valves need external ancillaries to operate the valves and thus are not 
suitable for portability.    
Alternatively, actuate-to-open valves are closed in their rest state.  These valves are operated 
by applying vacuum in the control layer, which causes the thin membrane to deflect upwards, 
allowing flow or mixing of the fluids in the fluid layer beneath.  These valves are closed at rest 
so devices based on these valves can be transported easily without leading to unwanted mixing. 
However they require selective reversible bonding of the fluid layer to the substrate so as to 
allow the multiple actuations of the valves.  These valves can be patterned much more densely 
than the actuate-to-close valves and thus are useful for fabrication of dense microfluidic 
networks.
94,97
  Figure 8 show some of the crystallization platforms which are based on the 
pneumatic valve networks.  These valves have significant potential in high throughput screening 
applications where portability is desired. 
In droplet based methods, a second type of microfluidic platforms that relies on two phase 
flow, protein crystallization takes place inside aqueous volumes of a mixture of protein and 
precipitant which are surrounded by an immiscible carrier fluid (e.g. oil) as shown in Figure 9
29-
31,80
.  The crystallization trials can be conducted in tubes or capillaries made out of plastic or 
glass.  These methods allow for trials to be set up to mimic microbatch and vapor diffusion trials 
and allow for in situ analysis of crystals grown in the case where the capillaries are made out of 
22 
 
X-ray transparent materials
33
.  Recent advances have also allowed  lipidic cubic phase generation 
on these droplet based devices for carrying out in meso crystallization trials
80,99
. 
 
The SlipChip is an example of the third type of microfluidic platform in which the protein 
and precipitant are loaded into two different wells on different substrates which can slide relative 
to each other (Figure 9d).
46,80,100
  The motion of the plates brings the two solutions in contact, 
23 
 
thus driving protein crystallization.  In these chips, this relative motion of the wells is 
comparable to the valve actuation in the valve based devices.  This method enables exact 
metering of nanoliters of solution in to the wells on each of the plates which are then brought 
into contact.  One of the main advantages of this method is the simple operation of these chips, 
since the operation doesn’t need any external ancillary system to set up the actual trial. 
1.4 X-ray compatible microfluidic platforms for protein crystallization 
The challenge in implementing on-chip analysis on a microfluidic chip is finding a material 
which offers minimum scattering and attenuation from X-rays.  Once a suitable material has 
been identified design and fabrication of a microfluidic chip has to be developed to implement 
on-chip analysis on microfluidic platforms.  Traditional methods for protein crystallography 
involve looping the crystal out of the mother liquor and flash freezing it in liquid nitrogen.  This 
prevents formation of ice on the crystal.  The looped crystal can be used for cryogenic data 
collection.  While the mother liquor will still be present in most microfluidic systems, addition of 
cryoprotectant is possible to allow for cryogenic data collection.  Additional challenges in 
development of an on-chip microfluidic system pertain to device geometry and size so that it can 
be accommodated on present beamlines setup for X-ray data collection.  A chip which can be 
mounted on the current standardized setup on most synchrotrons would be highly beneficial as it 
can use the technology currently in place right away.   
X-ray capillaries have been traditionally associated with crystallography.  These capillaries 
are not always suited for protein crystallography especially under cryogenic conditions because 
of their length which can be several centimeters.  The long tubes are necessary to obtain the 
required distance for diffusion to occur and consequently grow many droplets of crystals.  
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However, during cryocooling, not all the drops in the long capillary can be cooled with the 
narrow cryostream which is only a few millimeters in diameter.  The remaining portion of the  
 
capillary will still be at room temperature and will act as a heat sink for the cooled part.  
Therefore, these conventional systems suffer from sub optimal cryocooling and ice formation.  
Microfluidic systems based on droplets in capillaries or tubes suffer from the same problems and 
require cutting out the region of interest or harvesting the crystal out of the device in order to 
collect data.  Microcapillary systems have been developed recently, which use X-ray transparent 
plastics so that on-chip data can be collected
43
.  However, the only reported structure from on-
chip data is for model proteins like lysozyme, for other proteins, they still have to harvest the 
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crystal form the capillary, and collect data under cryogenic conditions.  Figure 10 illustrates 
some of the platforms which are based on capillaries that have been developed for on-chip 
analysis. 
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Microfluidic chips for on-chip analysis require a different choice of material from traditional 
microfluidics.  The majority of microfluidic devices reported in the literature have been 
fabricated out of relatively thick layers of polydimethylsiloxane (PDMS) and glass, materials 
which result in significant attenuation of X-rays,
101
 thus rendering the devices unsuitable for in 
situ analysis.
27-32,34,35,74,80,102-104
   While materials like polyimide (PI), polycarbonate (PC), poly 
methyl methacrylate (PMMA), polystyrene (PS) and cyclic olefin copolymer (COC) which 
attenuate X-rays to a lesser extent have been used to make microfluidic devices,
49,63,66,69,105-110
 
these devices have been limited to single layer devices with little or no integrated fluid handling 
capabilities (Figure 11).  Simple counter diffusion and free interface diffusion based microfluidic 
chips have been fabricated and tested for on-chip protein crystallography, these devices usually 
comprise of microchannels molded into a plastic substrate which is X-ray transparent
56,63,111,112
.  
Figure 11 gives examples of various chips which have simple geometries and carry out protein 
crystallization by either counter diffusion or free interface diffusion. In all these examples, chips 
have been fabricated from thin layers of an organic based polymer to minimize the scattering and 
attenuation from X-rays.  The main issue with these devices is that they consist of relatively 
simple networks and are single layered devices that don’t have active fluid control which would  
be necessary for more involved experiments.  Apart from this, most of the experiments 
performed with these chips have involved data collection on a model protein, of which the 
crystallization condition and structure is already known.  Halazonetis et al., have created chips 
out of cyclic olefin homopolymer that can carry out microbatch and vapor diffusion trials on chip 
and is X-ray transparent
113
.  They have also successfully crystallized two novel proteins on-chip  
but do not report on-chip diffraction data from the same, the only on-chip data they show is again 
from model systems like lysozyme.  X-CHIP
114
 (Figure 11) is another recent platform that allows 
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for data collection without manual harvesting of the crystals.   While they have successfully 
collected phasing information from multiple crystals at room temperature, they have not utilized 
it for solving the structure of a protein or commented on the phasing data quality.  Therefore, it 
still remains to be seen whether these devices can be used for screening conditions for new 
proteins and solve the structure from high resolution diffraction data collected on-chip.  The few 
instances in which a multi-layer device was used for novel protein structure determination, 
involved punching out the area of interest for further analysis, which is not suited for high 
throughput crystallography
56,112,115
. 
1.5 Conclusions 
Protein crystallization still remains an art instead of a science. Currently, no methods exist 
for predicting crystallization conditions a priori and this makes it necessary to set up of 
thousands of crystallization screening trials before identifying one or more suitable condition. 
Even after obtaining such a condition, a protein structure is not guaranteed through traditional 
methods as the crystals grown may not be of high quality or large enough to yield good quality 
data.  Methods to carry out further studies of protein dynamics and interaction have not been 
fully developed yet. Manual handling of crystals is still required to harvest crystals out of the 
well or plates the trial has been set up in and subsequently loop them and cryo-cool the crystal, 
so that X-rays can be shot at them for structure determination.  Crystals that are fragile and small 
have the potential to be damaged during this step.  Automation of the crystal handling, the only 
manual step in the current process for protein structure determination, will obviate any human 
intervention once the trial has been set up.  Microfluidics has the potential to impact the field by 
facilitating on-chip screening, crystallization and eliminating handling of the crystals, followed 
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by on-chip X-ray analysis at biologically relevant temperatures thus facilitating studies of those 
targets for which cryo-compatible crystallization conditions cannot be found. 
The work described here hopes to address these challenges.  In Chapter 2, new protocols for 
fabrication of a hybrid microfluidic platform fabricated out of COC, which is X-ray transparent, 
has been described.  This platform would allow on-chip analysis of protein crystals while 
retaining the functionality and fluid control of a complex microfluidic network on-chip. 
Integrating this platform with current synchrotron facilities has also been discussed.  In Chapter 
3 validation of this platform with several model proteins is discussed. The data collection 
strategy for collecting data from multiple crystals and merging them to get a complete dataset is 
also discussed.  Chapter 4 discusses the application of this platform for screening, crystallization 
and de novo structure determination via on-chip phasing of a novel protein PhnA.  In Chapter 5, 
the development of a microfluidic approach to microseeding is presented.  Crystals of 
photoactive yellow protein are grown via microseeding on-chip and diffraction data from the 
crystals are collected.  Chapter 6 discusses a method to collect functional information from 
protein crystals via Laue crystallography.  This is the first time that a microfluidic chip has been 
used for collecting time resolved diffraction data on multiple proteins.  
Microfluidic platforms have tremendous potential to address many problems with respect to 
studying difficult systems in structural biology. The first step to realize this potential is to 
validate a robust platform that can screen multiple crystallization conditions and allow in situ 
structure determination of novel proteins.  Later, this platform can be adapted to study various 
aspects of dynamic crystallography, including protein folding and kinetics, and interaction with 
other biomolecules. 
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Chapter 2
1
 
Fabrication of X-ray compatible microfluidic platforms for 
protein crystallization 
 
2.1 Introduction 
This chapter reports a method for fabricating multilayer microfluidic protein crystallization 
platforms using different materials to achieve X-ray transparency and compatibility with 
crystallization reagents.  Design and fabrication of a microfluidic chip with an array of 
crystallization wells for screening different conditions that consume a minimal amount of protein 
solution as compared to traditional screening methods is described.  A large number of high 
quality isomorphous protein crystals can be grown in the wells, after which slices of X-ray data 
can be collected from many crystals still residing within the wells.  Complete protein structures 
can be obtained by merging these slices of data followed by further processing with 
crystallography software.  This approach of using an x-ray transparent chip for screening, crystal 
growth, and X-ray data collection enables room temperature data collection from many crystals 
mounted in parallel, which thus eliminates crystal handling and minimizes radiation damage to 
the crystals.   
Microfluidic platforms have gained widespread use in diverse fields like chemical synthesis, 
enzymatic and DNA analysis 
1,2
, proteomics 
3,4
, point-of-care, medical and clinical  
                                                     
1
 Part of this work has been published in S. Guha et al., Senors and Actuators B, 2012, 174, 1-9. 
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diagnostics 
5-7
, energy conversion 
8,9
, and protein / pharmaceutical crystallization 
10-14
.  
Microfluidics offers several advantages in terms of reduced sample size and easy preparation, 
fine control over transport phenomena on the microscale, ease of scalability, detection and 
sample analysis on a single, integrated platform 
15,16
.  A large fraction of microfluidic devices 
reported in the literature to date have been fabricated using poly(dimethylsiloxane) (PDMS) and 
glass, which allow for rapid prototyping 
13,17,18
.  Issues still exist, however, with respect to 
compatibility with different chemistries, temperature and pressure variation, as well as 
amenability to integration of analysis techniques.  Many alternative materials and combination of 
materials have been explored for the fabrication of microfluidic platforms with the goal to 
overcome these issues for specific applications
19,20
.  Typical challenges encountered in these 
efforts are bonding of different materials, interfacing with ancillary equipment, and the assembly 
of chips comprised of highly integrated, complex designs. 
The focus of this work is on the application of microfluidic platforms in structural biology, 
specifically for protein crystallography.  Protein structure determination involves handling of 
small sample volumes, fine control over transport properties during crystallization, and requires 
the collection and analysis of X-ray diffraction data from the crystals formed
21-23
.  A microfluidic 
approach has the potential to meet these requirements.  For example, our group recently reported 
a microfluidic array chip for solid form screening of candidate pharmaceuticals 
14
, but these 
chips lacks X-ray transparency.  The first step in protein crystallization involves screening a 
protein against a wide range of precipitants to identify suitable crystallization condition(s).  Once 
one or more conditions have been identified, traditional methods require the crystals to be 
manually harvested, cryo-cooled and mounted in an X-ray beam for structure determination, all 
one crystal at a time.  These challenging tasks, especially when crystals are small and fragile, 
often damage the crystal, affecting the quality of data collected.  Several of the microfluidic 
platforms reported in the literature have tried to address these challenges, however most of them 
still require the crystal to be manually harvested before data collection
12,13,24,25
.  X-ray 
transparent platforms have also been reported, but they have been limited to relatively simple, 
single-layer designs 
11,19,26,27
 that do not take advantage of the integrated fluid handling 
capabilities of multilayer microfluidics or require cutting out the section containing the crystal 
from the whole chip for further analysis 
28
.   
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Here I report on the fabrication of a microfluidic platform that allows for (i) screening up to 
100 crystallization conditions while consuming minimal amount of protein solution, (ii) on-chip 
X-ray data collection from the protein crystals grown, while (iii) retaining the fluid routing and 
manipulation capabilities of integrated, valve-based high throughput microfluidic systems.  This 
is achieved by assembling a thin hybrid microfluidic chip comprised of layers of cyclic olefin 
copolymer (COC) and PDMS.  I later will validate the utility of this chip and its use by 
crystallizing various proteins on-chip, followed by X-ray diffraction data collection from the 
crystals grown while they still reside within the microfluidic platform mounted as a whole in the 
X-ray beam (subsequent chapters). 
 
2.2 Materials and methods 
2.2.1 Fabrication of microfluidic platforms 
Silicon wafers were patterned using negative photoresist SU8-25 and SU8-2050 
(MicroChem).  The microfluidic platforms consisted of different layers of polymers.  The control 
layer was fabricated with COC (TOPAS Advanced Polymers Inc, 4 mil).  Patterning of the COC 
was performed via hot embossing at 175°C (Tg+50°C), using a master made out of a high 
temperature epoxy resin (Conapoxy FR 1080, 83:100 hardener: epoxy, by mass) using a hot 
press (Carver hot press, model 3851-0).  
The fluid layer was fabricated out of PDMS (General Electric RTV 615, Part A/B).  Inlets 
were drilled using a 750 µm drill bit (McMaster Carr).  Bonding of the fluid and control layer 
(see SI for further details) was done using a 1% (v/v) solution of 3-
glycidoxypropyltrimethoxysilane (GPTMS, Sigma Aldrich) and a 1% (v/v) solution of 3-
aminopropyltrimethoxysilane (APTMS, Sigma Aldrich).  The completed assembly was placed 
on a flat COC substrate prior to setting up of crystallization trials.  The use of vacuum for the 
operation of the devices eliminated the need to bond the fluid layer irreversibly to the COC 
substrate.   
All solutions were introduced on-chip by pipetting 2-4 µL of protein/precipitant solution on 
the inlet ports, then pulling the fluid into the chip by actuation of the appropriate valves by 
applying vacuum through a manifold (Cole Parmer) attached to a vacuum pump (GAST; Model 
DOA-P704-AA).  The vacuum was applied onto the chip through 24 gauge AWG, thin walled 
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PTFE tubing (Cole Parmer) connected to a block of PDMS, which was positioned over the 
appropriate control line inlet.  Once the chip was filled, all the inlets were covered with Crystal 
Clear Tape (Hampton HR4-511) to prevent evaporation and the trials were incubated.  Even 
though there is some loss of solution through the thin layer of PDMS, experiments have shown 
that trials in these chips can be incubated for up to 2 weeks.  
2.3 Results and discussion 
2.3.1 X-ray compatibility and materials characterization 
Attenuation of X-rays can be calculated for a particular energy based on the exponential 
decay in intensity of a narrow beam of monochromatic photons from an incident intensity I0 as it 
passes through a material of thickness x with a linear attenuation coefficient of the material μ 
29,30
. 
 0 exp xI I            (1) 
Attenuation coefficients have been well studied and documented for elemental materials 
29
.  
For a compound containing multiple elements, a linear attenuation coefficient can be calculated 
based on the sum of the contribution to attenuation from each of the individual elements i, 
weighted based on their mass fraction wi.   
i iw             (2) 
 Table 1 lists the atomic mass fractional compositions of various materials commonly used in 
microfluidic device manufacture and shows calculated values for the linear attenuation 
coefficients for SiO2, PDMS, COC, PMMA and PI as a function of photon energy.  Soft X-rays 
(lower energy) attenuate much more strongly than do harder X-rays (higher energy), thus the 
energy of X-rays used for an experiment can have a significant effect on the signal observed 
from a device.  Using values for the attenuation coefficient for X-rays with a wavelength of 1Å 
(12.4 keV), the transmission factor I/I0 can be calculated as a function of material thickness using 
Eq. 1.  
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Several interesting observations can be made from the data presented in Table 1.  PDMS and 
PMMA have very similar densities; however the linear attenuation coefficient for PDMS is 
significantly higher.  This difference arises from the silicon content in PDMS.  Heavier atoms 
present a larger cross-section for interacting with photons and will thus cause a larger degree of 
attenuation.  The density of a material also plays a role in the degree of attenuation observed, 
Table 1. Atomic mass fraction density and a calculated value for linear attenuation coefficient µ at 1Å 
(12.4keV) for various materials used in microfluidic devices.   SiO2 = quartz 
31
,  PDMS = 
polydimethylsiloxane (Si61O60C124H368) 
30
,  COC = cyclic olefin copolymer (C9H14) 
32
, PMMA = 
polymethylmethacrylate (C5H8O) 
30
, PI = polyimide (C22H10N2O5) 
33
. 
Element SiO2 PDMS COC PMMA PI 
H -- 0.081 0.116 0.096 0.026 
C -- 0.329 0.885 0.714 0.692 
N -- -- -- -- 0.073 
O 0.533 0.212 -- 0.190 0.209 
Si 0.467 0.378 -- -- -- 
Density (g/cm3) 2.65 0.92 1.02 0.94 1.42 
µ at 1Å (cm-1) 9.330 7.334 1.131 1.472 1.618 
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with higher density 
materials increasing the 
number of atoms which can 
interact with a photon for a 
given path length, though 
this effect is less significant 
than elemental composition. 
 
Knowing the attenuation 
coefficient for various 
materials, an expression for 
the attenuation through a 
series of films of thickness j 
can be calculated based on 
Eq. (1). 
 0 exp j jxI I   ...(3) 
A typical device used here 
has an X-ray path length of 
145 µm of COC and 20 µm 
of PDMS (50 µm COC 
substrate, 20 µm PDMS 
membrane, 75 µm COC 
control layer).  PDMS and 
COC show a characteristic 
scattering pattern that can be 
observed in the diffraction 
data collected on-chip.  
However this scattering pattern occurs at relatively low angles of q-spacing or areas of low 
resolution diffraction (5.2Å for COC and 7.5Å for PDMS) and does not affect the data collected 
at higher resolution (Figure 12).  
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In designing an X-ray compatible microfluidic device for use in protein crystallography three 
main considerations with respect to the interaction between materials and X-rays must be taken 
into account: (i) attenuation and (ii) scattering of X-rays passing through device materials, and 
(iii) the strength of diffraction resulting from a crystal.  Attenuation originates from the 
absorption of photons by the material, thereby decreasing the intensity of both the incident X-ray 
beam and the resulting diffracted X-rays.  Scattering is an elastic redirection of photons based on 
the internal structure of the material and can affect the signal-to-noise ratio.  The strength of the 
diffraction signal from a crystal is related to not only the degree of order within the crystal, but 
also the packing density and the size of the crystal 
34-38
. 
Figure 13a shows the variation of the linear attenuation coefficient with the X-ray energy.  In 
general, the linear attenuation coefficient is lower at higher X-ray energy.  At relevant energies 
for X-ray data collection (here 12.4 keV), COC attenuates X-rays seven times less than PDMS 
and SiO2.  Figure 13b shows the transmission factor for COC and PDMS as a function of film 
thickness.  A thickness exceeding 3 mm is typical for conventional microfluidic devices, at 
which point the transmission factor is less than 10% (Figure 12b).  However for the hybrid COC-
PDMS device as reported here, the transmission factor was more than 90% (Figure 13a, dotted 
line shows data collection energy of 12.4 keV).  An analysis of both PDMS and COC shows that 
these materials produce a characteristic scattering pattern, seen in the form of rings in magnified 
diffraction data.  However this scattering occurs at relatively low resolution and does not impact 
the collection of high resolution diffraction data. 
2.3.2 Design and operation of microfluidic devices 
The microfluidic device presented here enables the screening of protein solution against 
different precipitants, and also allows for structure determination of the protein once a suitable 
crystallization condition has been found.  The main challenge here is to create a microfluidic 
chip that is still capable of fluid routing and compartmentalization to allow screening of many 
conditions, while also being X-ray transparent. 
Array chip fabrication 
As discussed above, I chose to replace the traditionally thick layers of PDMS with thin films 
of COC because of its lower X-ray attenuation profile and beneficial material properties.  
However, COC is not suitable for the integration of valves into a microfluidic device because it 
does not have the same degree of flexibility as PDMS, an essential property for typical 
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pneumatic valves 
39
.   To retain the ability to route and compartmentalize fluids on-chip, I use a 
thin layer of PDMS sandwiched between COC layers.  This hybrid approach eliminates the bulk 
of PDMS usually found in traditional devices.  Using a 20 µm PDMS layer sandwiched between 
two COC layers has only a minimal effect on the transmission of X-rays at energies relevant for 
X-ray data collection (Figure 13a).   
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The hybrid microfluidic chips are comprised of a thin PDMS fluid layer sandwiched between 
and bonded to a COC control layer and flat COC substrate (Figure 14a).  The control layer is 
fabricated via hot embossing against an epoxy master.  This epoxy master is a fabricated by first 
creating a photoresist-on-silicon master using standard photolithography, followed by replication 
of this silicon master into a PDMS mold, which in turn is replicated in epoxy 
20
.  Sheets of COC 
(100 µm) were patterned with this epoxy master by hot embossing at 175°C (Figure 14a).  The 
COC control layers have 25 µm deep and 50 µm wide negative relief patterns as the control 
lines.  Figure 15 shows the fidelity of pattern transfer into COC.  Inlet holes for actuation of 
valves were then drilled in the COC control layer.   
 
The fluid layer is fabricated in PDMS using standard soft lithography 
39
, with the COC 
control layer being bonded to the 70 µm thick fluid layer before being lifted from its photoresist 
mater 
40
.   A perspective view of this assembly is shown in Figure 14b.  The COC control layer 
was chemically bonded to the thin PDMS fluid layer.  Initial simple well devices were bonded 
using an oxygen plasma treatment while array chips with dense valve networks, utilized cross-
linking between an epoxy-terminated silane on the surface of the control layer and an amine-
terminated silane on the surface of the fluid layer (Figure 16) 
40
.  A 60 second oxygen plasma 
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treatment was used to activate the PDMS and COC surfaces for the formation of a silane bond.  
The COC control layer was immersed in a 1% (v/v) solution of 3-
glycidoxypropyltrimethoxysilane (GPTMS) and the PDMS fluid layer was immersed in a 1% 
(v/v) solution of 3-aminopropyltrimethoxysilane (APTMS) for 20 minutes.  After rinsing with DI 
water and blowing dry with nitrogen the two layers were aligned and brought into contact.  A 
strong bond forms almost immediately and the assembled structure was allowed to cure for 1 
hour at room temperature 
40
.  Because of the nature of the normally closed valves, it was not 
necessary to bond the device to the 
COC substrate 
41,42
.  To further decrease 
the thickness of the chip, Duralar (0.5 
mils) was used as a substrate.  Inlet 
holes for the fluid layer were then 
drilled through this composite 
assembly.  Lastly, this COC-PDMS 
assembly was placed on a 50 µm thick 
COC sheet to close the fluid channels.   
The fabrication material described 
above was successfully used to create 
and test 24- and 96-well array chips for 
on-chip collection of X-ray diffraction 
data.  However, the success rate in 
fabricating denser and larger array chips 
with this fabrication protocol was low.  
This was mainly due to the challenges 
of aligning the hot pressed control layer successfully over the fluid layer.  The two main issues 
were, (a) the APTMS-GPTMS bonding strategy meant that only one attempt could be made at 
aligning the two layers, since the bond was immediate and irreversible, and (b) the hot 
embossing created a factor of expansion in the COC control layer which made alignment of the 
96-well array chips very cumbersome.  Though the 24-well devices had an excellent success rate 
(>90%), the number of working 96-well chips was low.  For high throughput screening it was 
 45 
essential that the 96-well array chip be easy to fabricate, so I worked on an alternative fabrication 
protocol. 
To address the two main issues, hot embossing and irreversible bonding, one method that 
could be used was to make the control and fluid layer both out of PDMS.  These PDMS layers 
would have to be very thin so as to ensure that the new device geometry was still X-ray 
transparent.  Conventional soft lithographic procedures utilize a thick PDMS control layer to 
ensure easy bonding to a thin fluid layer, a strategy that would not work in this case.  Some other 
material would have to be used to lift off the control layer and provide the requisite stiffness to 
the control layer for it to be bonded to the fluid layer.  I used COC as that material, because it 
was already proven to be X-ray transparent and was much more rigid than PDMS.   
 
In the new fabrication scheme (Figure 17), the features for the control layer were fabricated 
via patterning photoresist on silicon wafer followed by spin coating a thin layer of PDMS (5:1) 
onto it.  This PDMS control layer was baked at 70°C for 10 minutes (until the PDMS was just 
slightly tacky).  A 2 mil COC sheet was then plasma treated along with this PDMS coated wafer 
for a minute and then the two were brought into conformal contact and baked for an hour at 70°C 
to ensure bonding.  The COC-PDMS control layer was then peeled from the control layer master 
and the exposed PDMS side was covered with scotch tape and holes were drilled for the inlets.  
The fluid layer was prepared in the same manner as before.  The partially cured 15:1 PDMS on 
the fluid layer master was then placed under the microscope and the COC attached control layer 
was aligned over it.  Since this was bonding between two PDMS layers, the bonding was 
reversible and allowed greater ease in alignment of the features, especially for larger array chips.  
Other lab members have successfully aligned 192-well array chips using this technique proving  
 46 
 
its reliability and robustness.  The aligned fluid and control layer assembly was then baked in the 
over for four hours to ensure robust bonding.  Following this, the assembly was carefully peeled 
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off the wafer, and holes were drilled for the fluid inlets.  This completed assembly was then 
placed on a thin COC substrate to complete the fabrication. 
Design of array chips 
The array chips consist of a series of separate half-wells for protein and precipitant solutions 
arranged in columns.  Each of these individual wells is a separate crystallization trial (Figure 
18a) and is isolated from the rest of the wells using a series of normally-closed valves (Figure 
18a, green and blue valves) 
43
.  Since these valves are closed at rest, the chip can be transported 
easily after filling without disturbing the crystallization trials.  Each half-well contains 50 nL of 
solution and the entire chip uses just 1.4 µL of protein solution for a 24-well design.  These 
adjacent half wells are separated by a normally closed valve that allows mixing between the 
protein and precipitant solution through free interface diffusion.  The time required to mix two 
solutions in adjacent wells can be estimated using Fick’s law, t = x2/(4D), where x is the 
combined length along which the two solutions are mixing and D is the diffusivity of the 
diffusing species (protein in this case, approximately ~10
-6
 cm
2
/s).  For a mixing length of 
around 1 mm, the time needed to mix two solutions is approximately 20 minutes.  The mixing 
time can be adjusted for other protein solutions with different diffusivities.  
2.3.3 Array chip operation 
The two half-wells are filled independently of each other using dedicated valve lines (blue 
and green valves for the aqueous protein and precipitant solutions respectively; see Figure 14a) 
for each set of half-wells arranged in columns.  These valves are closed at rest thus isolating the 
various chambers.  The mixing valves (pink in Figure 18) between adjacent half-wells enable the 
protein and precipitant solution to mix by diffusion.  The entire filling process is illustrated in 
Figure 18.  First 2 µL of protein solution is pipetted over the inlet of the protein line and vacuum 
is applied to the protein valve line (blue) which allows for dead-end filling of the protein solution 
into the series of protein half-wells (Figure 18b).  Once the protein solution has been introduced, 
the protein valve set is closed, isolating the solutions in the protein chambers.  Next, 1 µL 
droplets of precipitant solution are pipetted over the inlets of each of the six precipitant.  Vacuum 
is then applied via the precipitant valve lines (green) and the precipitant solutions flow into the 
appropriate half-wells (Figure 18c).  After closing the precipitant valve set, thus locking the 
precipitants in their respective chambers, the inlets for filling and actuation are sealed with  
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Crystal clear tape, preventing evaporation of the filled solutions.  Next, the mixing valves (pink) 
located between the protein and precipitant chambers are actuated, allowing sets of two adjacent 
solutions to mix by free interface diffusion (Figure 18d).  I allowed the solutions to mix for 20 
minutes for all experiments performed here.  After mixing, the mixing valves are closed, the 
inlets of these control lines are sealed with Crystal Clear tape, and the chips are incubated at 
either 4°C or room temperature for 8-48 hours.  Previously, we have used a similar microfluidic 
array chip for solid form screening of candidate pharmaceuticals 
14
, but this platform lacked X-
ray transparency.  
2.3.4 Single-well chip design, operation, and proof-of-concept experiments 
 
Before completing the full design and fabrication of the 24-well array chip, I wished to confirm 
that indeed high quality diffraction data can be collected from crystals residing inside a 
microfluidic well comprised of COC layers as well as a thin PDMS layer (Figure 19).   These 
chips for validating the X-ray compatibility of the materials are made using a similar fabrication 
scheme described earlier (Section 3.2.1).  They consist of a large rectangular 2.36 mm by 3.36 
mm by 25 µm wells with a volume of 0.2 µL.  Six posts were fabricated within the fluidic well 
chamber to provide support for the thin PDMS membrane.  The COC control layer consisted of 
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an identical sized chamber aligned directly above the fluid well (Figure 19).  Pre-mixed solutions 
of protein and precipitant (see Materials and Methods) were introduced into the chip by pipetting 
a drop over the inlet of the fluid layer and pulling it into the fluid layer well by applying vacuum 
to the inlet of the control layer (Figure 19).  The chip was allowed to incubate for 48-72 hours.   
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To test the effectiveness of the chip materials for on-chip X-ray data collection, I first grew 
crystals of model proteins lysozyme, ribonuclease A, and thaumatin in single well chips.  The 
whole chips were then mounted onto a goniometer mount and taken to Argonne National Lab 
(LS-CAT).  Further discussion of the on-chip data quality is discussed in Chapter 3. 
2.3.5 Interfacing with beamline infrastructure and data collection strategy 
The chips described above are X-ray transparent and can be used for data collection from 
crystals grown on-chip.  In order to collect data from the 3
rd
 generation synchrotron sources,  
which enable data collection at extremely high speeds, it is necessary that the chip be compatible 
with the infrastructure already present there with minimum modifications to the current setup.  
The University of Illinois has collaboration with LS-CAT (Life Sciences Collaborative Access 
Team) at the Advanced Photon Source in the Argonne National Lab in Chicago.  LS-CAT is set 
up for macromolecular crystallography and the crystals are mounted on the beamline using a 
magnetic goniometer mount that has a loop for scooping out the crystal.  To utilize the same 
setup with minimum modification, I modified the goniometer mount for single crystal studies to 
fit the microfluidic chip.  To achieve this, I cut off the stem which holds the crystal loop, and 
glued a metallic cylinder to hold the chip.  This cylinder was machined in order to have a slit 
running down the top, with an attached set screw to hold the chip in place.  Figure 20 shows in 
further detail the modified goniometer mount for holding the chip and how it interfaces with the 
setup at LS-CAT.  Being able to mount the chips on to the beamline with minimum alteration to 
the setup at LS-CAT ensures that we can use the excellent sample visualization aids already 
present to locate and shoot individual crystals on the chip with great precision. 
2.3.6 Screening and on-chip protein structure determination  
Identification of suitable crystallization conditions by screening protein solution against a 
wide variety of crystallization mixtures (cocktail of salts, buffers and precipitants) is the first step 
in the process of protein structure determination.  Chapters 3 and 4 will discuss this further.  In 
general, a series of array chips was used to set up to conduct screening experiments where a 
protein was screened against a library of different conditions.  These experiments were generally 
carried out in larger 96-well array chips where the size of the protein and precipitant chambers 
were varied along the vertical to cover a larger chemical space in terms of the concentration of 
the protein and the precipitant.  The fabrication of these chips is identical to the method  
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described earlier in the chapter.  Figure 21 shows schematics of the both 24- and 96- well 
variants of the array chip.  Once a suitable condition had been identified, the same condition was 
set up in replicate on the 24-well array chip (with identical wells) to grow a large number of 
isomorphous crystals for diffraction data collection.  The 24-well chips were small enough to fit 
in the X-ray beam without further modification and were perfect for on-chip data collection.  
Note that typical microbatch wellplate experiments need 2 µL of protein solution per 
condition whereas a whole 24-well array chip can be filled using less than 2 µL of protein 
solution.  These chips truly scale down the crystallization trials that are performed in usual 
biochemistry and structural biology labs.  
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The microfluidic array chips were validated for crystallization screening experiments using 
various model and novel proteins that will be discussed in later chapters.  X-ray compatibility of 
the chip allowed us to easily identify whether the hits were indeed protein crystals or just salt 
crystals using either a local X-ray source (Bruker APEX) or the APS.  The variability between 
results from the microbatch well plate and our chip can be explained by (i) differences in the 
method of mixing of protein and precipitant solutions; (ii) slow concentration of solutions in the 
microfluidic chips over time; and (iii) the stochastic nature and variability of crystallization 
trials
44-46
.   
2.4 Conclusions 
In summary, the microfluidic platform reported here allows for crystallization screening and 
subsequent on-chip X-ray data collection of crystallized proteins.  The fabrication scheme uses a 
combination of COC and PDMS layers, and yields a platform that retains fluid routing 
capabilities via pneumatic valving while also achieving X-ray transparency.  The dense network 
of integrated pneumatic valves allows for fast and easy setup of the crystallization screens, which 
in turn facilitates the reproducible growth of a large number of isomorphous crystals.  The valves 
are only opened by vacuum actuation during filling and mixing.  The valves are closed in rest, so 
the individual crystallization trials are isolated during crystallization and data collection in the 
absence of connections with ancillary equipment.  The whole chip can be transported to and 
mounted in the X-ray beam for collection of diffraction data wedges from many crystals still 
residing on chip at room temperature.  By merging these wedges of data a complete data set for 
full structure determination is obtained.  This approach eliminates the need for crystal harvesting 
and cryo-cooling, while it simultaneously avoids the detrimental effects of the effects of 
radiation damage associated with room temperature data collection. 
Going forward, the X-ray compatible microfluidic chip reported here can be used to solve 
structure of novel proteins, especially those that (i) yield small, fragile crystals, (ii) have no 
known cryogenic crystallization conditions, and/or (iii) have been known to yield low resolution 
data using traditional cryogenic data collection.  In addition to allowing for the routine collection 
of static structural information of proteins at biologically relevant temperatures as reported 
above, the fine control over transport phenomena coupled with on-chip analysis capabilities 
offered by these microfluidic platforms could enable a range of other biological studies.  For 
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example, precise microfluidic fluid handling could be utilized to enable dynamic structural 
studies based on the addition of various stimuli such as ligands, electrochemical agents, 
acid/base to affect the pH, or even changes temperature.  Such studies have the potential to shed 
light on structural changes associated with protein function in unprecedented ways.  
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Chapter 3
2
 
Proof of concept studies for on-chip X-ray diffraction data 
collection from soluble proteins 
3.1 Introduction 
Protein structure determination via X-ray diffraction is a critical aspect of structural biology.  
Knowledge of the three dimensional structure of a protein provides insight into the mechanism 
whereby these complex macromolecules function, as well as into potential sites for drug 
targeting 
1-3
.  Recent efforts in structural biology have produced not only a large number of 
protein structures, but have helped to lessen bottlenecks 
4,5
, leading to improved, and often 
automated, high throughput methodologies for the cloning, expression, purification, 
crystallization, and X-ray diffraction analysis of novel protein targets 
6-15
.  These approaches 
frequently take advantage of robotics 
8-12,14,16
 and/or microfluidics 
17-29
.  With these 
improvements, the harvesting and mounting of crystals for X-ray analysis remains the only 
manual step in the structural biology pipeline 
10,30,31
. 
Protein crystallization and structure determination is an intensive multi-step process.  Each of 
the steps of identification and optimization of crystallization conditions, determination of 
appropriate cryoprotection conditions, and examination of heavy atom derivatives or ligand 
binding represents a significant screening effort in the lab coupled with harvesting of individual 
crystals for X-ray diffraction analysis.  However, the scale of these efforts can be hampered both 
by limitations on the quantity of available protein and the difficulties associated with manual 
harvesting of fragile protein crystals. 
                                                     
2
 Part of this work has been published in S. Guha et al., Senors and Actuators B, 2012, 174, 1-9. 
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Current methodologies in protein crystallography rely on collecting structural data from a 
single crystal at cryogenic temperatures to minimize the effects of radiation damage while 
avoiding concerns of crystal-to-crystal variability
15,32-37
.  This requires harvesting individual 
protein crystals from the crystallization droplet in which they were grown.  However, both the 
physical handling associated with this process and exposure of the crystal to the ambient 
environment have significant potential to damage the crystal
21,35,38,39
.  Furthermore, the 
cryocooling process has been shown to induce crystal damage, although cryoprotection strategies 
attempt to minimize these effects
15,32,33
.  As a result of this single-crystal paradigm, crystals that 
are not amenable to cryo-crystallography or are highly sensitive to X-ray radiation may prove so 
difficult to work with that they are abandoned in favor of searching for new crystallization 
conditions that do not suffer from these limitations. 
Microfluidic approaches for crystallization provide more precise control over the 
composition and kinetic parameters of a crystallization experiment than what is accessible at 
larger scales 
17-29
.  However, difficulties associated with harvesting crystals from these devices 
hamper their use.  The crystal harvesting challenge could be mitigated by mounting X-ray 
transparent microfluidic chips directly in the X-ray beam.  Unfortunately, the typical size and 
planar design of microfluidic chips limit rotational freedom and are incompatible with current 
methods for cryocooling.  Data collection strategies, including how anomalous diffraction data is 
collected, will have to be adjusted to overcome the latter two chip-related challenges. 
The majority of microfluidic chips reported in the literature have been fabricated out of 
relatively thick layers of polydimethylsiloxane (PDMS) and/or glass, which are incompatible 
with the requirements for high quality on-chip X-ray diffraction analysis 
17,23,29,40
.  The designs 
of X-ray compatible microfluidic chips reported in the literature that are based on materials like 
polyimide, poly(methyl methacrylate), and cyclic olefin copolymer (COC) have been relatively 
simple and typically do not take advantage of the high throughput integrated fluid handling 
capabilities characteristic of multi-layer PDMS chips 
18-21,28,41,42
.  In those cases where X-ray 
data was collected from a multi-layer chip, the wells with crystals were punched out from a 
larger chip prior to analysis, a strategy that is not suited for high throughput crystallography 
23,43,44
.  Furthermore, none of the reported examples have been utilized for the collection of 
anomalous data, most likely due to the more stringent signal-to-noise requirements. 
 59 
In this chapter, I utilize the microfluidic chips described in Chapter 2 that retain the 
integrated fluid handling capabilities of traditional multi-layer devices, necessary for high 
throughput crystallization, while achieving a high level of X-ray transparency.  A comparison of 
traditional methods as well as on-chip methods for performing standard crystallization screens is 
presented.  I validated the utility of this chip and its use by crystallizing the soluble proteins 
lysozyme, thaumatin and ribonuclease A on-chip, followed by X-ray diffraction data collection 
from the crystals grown while they still reside within the microfluidic platform mounted as a 
whole in the X-ray beam. 
3.2 Materials and methods  
3.2.1 Protein solutions  
Hen egg white lysozyme (Sigma) was dissolved in 50 mM sodium acetate (Sigma-Aldrich) at 
pH 4.6 with 20% (w/v) glycerol (Fisher Scientific) at a concentration of ~100 mg/mL.  
Lysozyme concentrations were determined by UV absorbance measurements (Lambda 650 UV-
Vis spectrophotometer, Perkin Elmer) at 280 nm using an extinction coefficient of 2.64 mL/(mg-
cm) 45.  For proof-of-concept crystallography experiments precipitant solutions of 1M and 2M 
NaCl (Aldrich) in 50 mM sodium acetate, pH 4.6 with 20% (w/v) glycerol were prepared.  For 
screening experiments Hampton Crystal Screen chemicals were used directly (Hampton 
Research).   
Thaumatin from Thaumatococcus daniellii (Sigma) was dissolved in 100 mM NaH2PO4 
(EMD Chemicals) at pH 6.5 at a concentration of 82 mg/mL.  The protein concentration was 
determined by UV absorbance measurements at 280 nm using an extinction coefficient of 1.25 
mL/(mg-cm) 46.  A precipitant solution of 30% (w/v) Na/K tartrate (Malinckrodt) and 20% w/v 
glycerol in 100 mM NaH2PO4 pH 7.0 was used 47.   
Ribonculease A (R-5500, Sigma) from bovine pancreas was dissolved in 100 mM sodium 
acetate at pH 4.5 at a concentration of 229 mg/mL.  The protein concentration was determined by 
UV absorbance measurements at 280 nm using an extinction coefficient of 0.70 mL/(mg-cm).48  
A precipitant solution of saturated NaCl in 100 mM sodium acetate at pH 4.5 was used 49.   
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3.2.2 Fabrication and operation of microfluidic platforms 
Silicon wafers were patterned using negative photoresist SU8-25 and SU8-2050 
(MicroChem).  The microfluidic platforms consisted of different layers of polymers.  The control 
layer was fabricated with COC (TOPAS Advanced Polymers Inc, 4 mil).  Patterning of the COC 
was performed via hot embossing at 175°C (Tg+50°C), using a master made out of a high 
temperature epoxy resin (Conapoxy FR 1080, 83:100 hardener: epoxy, by mass) using a hot 
press (Carver hot press, model 3851-0).  
The fluid layer was fabricated out of PDMS (General Electric RTV 615, Part A/B).  Inlets 
were drilled using a 750 µm drill bit (McMaster Carr).  Bonding of the fluid and control layer 
(see SI for further details) was done using a 1% (v/v) solution of 3-
glycidoxypropyltrimethoxysilane (GPTMS, Sigma Aldrich) and a 1% (v/v) solution of 3-
aminopropyltrimethoxysilane (APTMS, Sigma Aldrich).  The completed assembly was placed 
on a flat COC substrate prior to setting up of crystallization trials.  The use of vacuum for the 
operation of the devices eliminated the need to bond the fluid layer irreversibly to the COC 
substrate.   
All solutions were introduced on-chip by pipetting 2-4 µL of protein/precipitant solution on 
the inlet ports, then pulling the fluid into the chip by actuation of the appropriate valves by 
applying vacuum through a manifold (Cole Parmer) attached to a vacuum pump (GAST; Model 
DOA-P704-AA).  The vacuum was applied onto the chip through 24 gauge AWG, thin walled 
PTFE tubing (Cole Parmer) connected to a block of PDMS, which was positioned over the 
appropriate control line inlet.  Once the chip was filled, all the inlets were covered with Crystal 
Clear Tape (Hampton HR4-511) to prevent evaporation and the trials were incubated.  Even 
though there is some loss of solution through the thin layer of PDMS, I have shown that trials in 
these chips can be incubated for up to 2 weeks.  
3.2.3 Visualization of crystallization experiments and setup of traditional crystallization 
trials   
Crystallization experiments were set up and visualized using either a stereomicroscope 
(Leica, MZ12.5) equipped with a digital camera (Leica, DFC295) or a computer controlled 
imaging system comprised of an optical microscope (Leica Z16 APO) equipped with an auto-
zoom lens (Leica 10447176), a digital camera (Leica DFC280), and a motorized x-y stage 
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(Semprex KL66) controlled by Image Pro Plus (Media Cybernetics).  Periodically birefringent 
images of the wells were taken.   
Traditional microbatch-under-oil crystallization trials were set up combining 2 µL each of 
protein and precipitant solutions in a Greiner well plate (Hampton Research) at room 
temperature.  Crystals were harvested using crystal mounts (Mitegen).  Crystallization trials of 
lysozyme were performed in traditional well plates, large well devices, and array chips at 4°C or 
at room temperature.  Crystallization trials for thaumatin and ribonuclease A were performed at 
room temperature. 
3.2.4 X-ray data collection 
The microfluidic chips were mounted on a standard magnetic goniometer mount (Hampton 
Research) with an attached metal tube into which a slit was cut.  A set-screw was used to secure 
samples.  Diffraction data was collected either at room temperature or under cryogenic 
conditions.  Cryo-cooling of samples was achieved by direct immersion into liquid nitrogen.  
Various sample-to-detector distances were used based on the quality of the crystal present.  
Typically data was collected using 1° steps with a 1s exposure at an X-ray energy of 12.7 keV (λ 
= 0.979Å) at Argonne National Lab (LS-CAT).  Data from multiple crystals in the microfluidic 
devices was collected over a range of 10° (-5° to +5° from the normal) and an optimal subset of 
the frames was subsequently merged to obtain a complete dataset.  Bench-top diffraction 
experiments were performed at the George L. Clark X-ray Facility at the University of Illinois 
using a General Area Diffraction Detector System (GADDS; Bruker) equipped with a four circle 
diffractometer and HiStar multiwire area detector.  A rotating anode generator (Bruker 
M18XHF22) operating at 40 kV and 60 mA was used with a graphite monochromator supplying 
a Cu Kα radiation beam (λ = 1.54Å or 8.048 keV).  The sample to detector distance is ~18 cm.  
Data was collected in a coupled mode where 2ω = 2θ such that multiple frames could be 
collected over a wider range of 2θ.  Typically two such frames were collected, spanning the 
range of 2θ from 0° to 40°, up to a resolution of 2.3 Å. 
Analysis of X-ray diffraction data collected at the synchrotron was performed using 
HKL2000 software for indexing, refinement, integration, and scaling (HKL Research) 50.  
Diffraction data collected at the University of Illinois was analyzed using GADDS software 
(version 4.1.08, Bruker AXS) and Topas 3 (Bruker AXS).  Subsequent processing of  
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crystallography datasets was done using the CCP4 suite of programs
51
.  Electron density maps 
were displayed using COOT
52
.  Molecular replacement
53
 for lysozyme was done using PDB 
structure 193L as the model
54
. 
3.3 Results and discussion 
3.3.1 Single-well chip design, operation, and proof-of-concept experiments 
Before completing the full design and fabrication of the 24-well array chip, I wished to 
confirm that indeed high quality diffraction data can be collected from crystals residing inside a 
microfluidic well comprised of COC layers as well as a thin PDMS layer.   These chips for 
validating the X-ray compatibility of the materials are made using a similar fabrication scheme 
described earlier (See Chapter 2).  They consist of a large rectangular 2.36 mm by 3.36 mm by 
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25 µm wells with a volume of 0.2 µL.  Six posts were fabricated within the fluidic well chamber 
to provide support for the thin PDMS membrane.  The COC control layer consisted of an 
identical sized chamber aligned directly above the fluid well (Figure 22a).  Pre-mixed solutions 
of protein and precipitant were introduced into the chip by pipetting a drop over the inlet of the 
fluid layer and pulling it into the fluid layer well by applying vacuum to the inlet of the control 
layer (Figure 22a).  The chip was allowed to incubate for 48-72 hours.   
To test the effectiveness of the chip materials for on-chip X-ray data collection, I first grew 
crystals of model proteins lysozyme (Figure 22c), ribonuclease A (Figure 22d), and thaumatin 
(Figure 22e) in single well chips.  The whole chips were then mounted onto a goniometer mount 
(Figure 22b) and taken to Argonne National Lab (LS-CAT).  The inlets in Figure 25c-e shows 
on-chip diffraction data collected from these chips from the different model proteins.  Even 
though a scatter ring from the materials is present, good quality, circular diffraction spots are still 
clearly visible, sufficient for structure determination. 
3.3.2 Screening and on-chip protein structure determination  
Identification of suitable crystallization conditions by screening protein solution against a 
wide variety of crystallization mixtures (cocktail of salts, buffers and precipitants) is the first step 
in the process of protein structure determination.  Figure 23 shows a 24-well array chip that 
allows for the testing of six different precipitant solutions in quadruplicate.  A series of array 
chips was used to test each of the individual conditions multiple times and the results were 
compared to those obtained using a traditional microbatch well plate.  
 
Table 1. Crystallization results of 100 mg/mL lysozyme in 50mM sodium acetate with 20% glycerol against the 50 
condition Hampton crystal screen at RT. 
    Condition 
number 
On-chipa/off-chipb 
    1 2 3 4 5 6 7 8 9 10 
    1-10 -
c
/- -/+
d
 -/- -/- -/- +/+ +/+ +/- +/+ +/+ 
    11-20 +/+ +/- -/- -/+ +/+ +/- +/+ +/+ +/- +/+ 
    21-30 +/- +/- +/- -/- +/+ -/- +/+ +/+ +/+ +/+ 
    31-40 +/+ +/- +/- +/+ +/+ -/- -/+ -/+ -/+ +/+ 
    41-50 +/+ -/- +/- -/- +/- +/- -/- +/+ -/- -/- 
    a Crystallization trials set up on a 24-well array chip.  b Trials set up on a microbatch 
tray under oil.  c “-” indicates absence and  d “+” indicates presence of crystals. 
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The microfluidic array chips were validated for crystallization screening experiments by 
testing solutions of lysozyme against the 50 condition Crystal Screen kit (Hampton Research) at 
room temperature.  After one week crystals were observed in 32 out of the 50 conditions in the 
array chips (Table 1) compared to only 26 hits in the microbatch wellplate.  X-ray compatibility 
of the chip allowed us to easily identify whether the hits were indeed protein crystals or just salt 
crystals using a local X-ray source (Bruker APEX, Table 2).  A comparison of the results 
obtained in the well plates versus the traditional microbatch method shows that 21 of the 
conditions produced crystals on both platforms while 5 conditions yielded crystals uniquely in 
the microbatch wellplates and 11 hits were observed uniquely in the microfluidic chips.  The 
variability between these results can be explained by (i) differences in the method of mixing of 
protein and precipitant solutions; (ii) slow concentration of solutions in the microfluidic chips 
over time; and (iii) the stochastic nature and variability of crystallization trials 
55-57
.  Note that 
typical microbatch wellplate experiments need 2 µL of protein solution per condition whereas a 
whole 24-well array chip can be filled using less than 2 µL of protein solution. 
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3.3.3 Strategy for on-chip data collection 
Once crystals have grown on-chip, I want to collect X-ray data with the crystals still residing 
in the microfluidic wells.  In tradition crystallography, crystals are manually looped out, cryo-
cooled, mounted in a cryo-stream, and rotated in the X-ray beam for data collection.  The 
dimensions and design of the array chips makes rotation of the chip for the collection of a 
complete dataset very difficult.  The chip is also too large to fit within typical cryo-streams on 
crystallography beamlines, necessitating data collection at room temperature.  Figure 24 shows a 
typical array chip mounted on one of the 
beamlines at the Advanced Photon Source 
(APS). 
The inability to utilize cryo-cooling to 
mitigate the effects of radiation damage 35 
led us to adopt an alternative strategy where I 
collect small wedges of data (10 degrees) 
from a large number of crystals at room 
temperature and later merge these wedges to 
form a complete dataset.  The use of small 
wedges of data limits the time of exposure, 
and thus the extent of radiation damage.  
These wedges can be merged to form a 
Table 2. Crystallographic data statistics from the analysis of a subset of the lysozyme crystals obtained in wells of the 
microfluidic array chip via crystallization screening using Hampton Crystal Screen.  Data was collected on-chip at room 
temperature.  Reported values are for all hkls.  Values shown in parenthesis represent the value for the highest resolution 
shell. 
Parameter 
Crystal Screen Reagent 
30 33 34 40 
Resolution 26 – 1.83 Å 26 – 1.80 Å 26 – 1.80 Å 26 – 1.60 Å 
Linear R-factor (Rsym) 0.056 (0.244) 0.046 (0.196) 0.041 (0.142) 0.047 (0.235) 
Mosaicity 0.08° – 0.26° 0.20° – 0.47° 0.15° – 0.20° 0.04° – 0.18° 
Redundancy 3.4 (3.0) 5.8 (4.2) 6.2 (5.8) 6.1 (5.2) 
Completeness 85.1% (87.2%) 97.2% (96.4%) 97.9% (97.7%) 99.9% (99.7%) 
Frames collected 39 78 80 80 
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complete dataset, provided that non-isomorphism between crystals is minimal and the orientation 
of the grown crystals is mostly random.  This method has been used previously to obtain 
structural information from tiny or fragile crystals or crystals which suffer from excessive 
radiation damage
58,59
.   
The advantage of applying this data collection strategy to crystals grown in a microfluidic 
chip is the ease by which a large number of crystals can be generated.  Furthermore, the fine 
control of transport on the microfluidic scale allows for 
improved reproducibility both in crystal quality and 
isomorphism between crystals grown in different wells 
or even in different chips.  Analysis of lysozyme 
crystals grown on-chip demonstrated that 98% of the 
crystals (47 out of 48) showed a coefficient of variation 
(standard deviation divided by the average) in the unit 
cell dimensions of ~0.1%. 
3.3.4 Analysis of on-chip collected X-ray data  
 I collected and analyzed room temperature X-ray 
data of lysozyme crystals grown in 24-well chips using 
the same crystallization conditions as used for the 
proof-of-principle experiments.  For comparison, I also 
collected X-ray data at cryogenic temperatures on a 
lysozyme crystal grown in a wellplate and mounted 
using a loop with Table 3 showing a comparison of the 
important crystallographic statistics between the two 
methods.   
Analysis of the crystallographic parameters and statistical measures of quality for both data 
collection and structural refinement via molecular replacement show that the quality of the data 
was not significantly affected either by collection at room temperature or because of the merging 
of data from multiple crystals.  The diffraction data was analyzed over the range of 50 – 1.55 Å 
(the diffraction limit for the on-chip data) to enable direct comparison between the other 
parameters.  Other data collection parameters such as Rsym, completeness, redundancy, and I/σ 
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and structural refinement parameters such as R/Rfree are comparable for the two cases, despite 
differences in crystal size, resolution, and signal-to-noise resulting from the presence of device 
materials.  Interestingly, due the absence of both physical handling and cryo-cooling, the 
mosaicity for the room temperature merged data is nearly an order of magnitude lower (i.e., 
better) than the mosaicity of the single-crystal cryogenic datasets.  Figure 25 compares the 
diffraction patterns and electron density maps obtained from the traditional, single-crystal 
cryogenic data and the on-chip, multi-crystal, room temperature data.  The high resolution data 
obtained in each of these cases is evident from the electron density maps of, e.g., aromatic amino 
acid side chains with the rings clearly visible.   
Table 3.  Crystallographic data statistics from the analysis of lysozyme crystals. 
Parameter On-Chipa Traditional (Cryogenic)b 
Unit Cell Dimensions 
a = b = 79.693Å  
c = 37.781Å 
a = b = 78.817Å 
c = 37.025Å 
Space Group P43212 P43212 
Observations (Unique) 783,994 (18,352) 223,433 (17,510) 
Resolution 50 – 1.55Å 50 – 1.55Å 
Rsym 0.064 (0.362) 0.052 ( 0.102) 
Mosaicity 0.03° – 0.08° 0.21° – 0.34° 
Redundancy 22.9 (5.7) 7.7 (7.7) 
Completeness 98.1% (83.4%) 99.7% (100%) 
I/σ 51.4 (3.9) 42.3 (19.4) 
# of Frames 363 100 
Refinement 
R (Rfree) 0.164 (0.227) 0.173 (0.276) 
Ramachandran Statistics 
Most Favored 96.1% (122) 96.1% (122) 
Allowed 3.9% (5) 3.9% (5) 
Disallowed 0.0% (0) 0.0% (0) 
a Merging of small datasets from "multiple crystals" analyzed on-chip within a 24-well device 
at room temperature.  b The "traditional" sample was grown using microbatch techniques and 
mounted using a standard crystal mount for cryogenic data collection.  Reported values are for 
all hkls.  Values in parenthesis represent the value for the highest resolution shell except where 
indicated for the number of observations as compared to unique reflections and R (Rfree) and 
for the Ramachandran statistics where the number in parenthesis indicates the number of 
residues in a given region.  Data was analyzed over the range of 50 – 1.55Å to enable a direct 
comparison with the data collected from merging the diffraction data taken from multiple 
crystals at RT. 
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3.4 Conclusions 
In summary, the microfluidic platform reported here allows for crystallization screening and 
subsequent on-chip X-ray data collection of crystallized proteins.  The fabrication scheme uses a 
combination of COC and PDMS layers, and yields a platform that retains fluid routing 
capabilities via pneumatic valving while also achieving X-ray transparency.  The dense network 
of integrated pneumatic valves allows for fast and easy setup of the crystallization screens, which 
in turn facilitates the reproducible growth of a large number of isomorphous crystals.  The valves 
are only opened by vacuum actuation during filling and mixing.  The valves are closed in rest, so 
the individual crystallization trials are isolated during crystallization and data collection in the 
absence of connections with ancillary equipment.  The whole chip can be transported to and 
mounted in the X-ray beam for collection of diffraction data wedges from many crystals still 
residing on chip at room temperature.  By merging these wedges of data a complete data set for 
full structure determination is obtained.  This approach eliminates the need for crystal harvesting 
and cryo-cooling, while it simultaneously avoids the detrimental effects of the effects of 
radiation damage associated with room temperature data collection. 
The screening capabilities of the platform were highlighted using a standard screen, followed 
by comparison of the results with the same screen performed via a traditional crystallization 
method.  The platform was validated by collecting data from several proteins like lysozyme, 
thaumatin and ribonuclease A.  By solving the structure of lysozyme using only diffraction data 
from many crystals residing on-chip I confirmed that the strategy of merging wedges of data 
from many crystals to obtain a complete dataset can be applied to these microfluidic platforms.   
Going forward, the methodology reported here can be used to solve structure of novel 
proteins, especially those that (i) yield small, fragile crystals, (ii) have no known cryogenic 
crystallization conditions, and/or (iii) have been known to yield low resolution data using 
traditional cryogenic data collection.  While proof-of-concept studies have shown that data can 
be collected from model systems, the real test will be whether it can screen conditions for novel 
proteins and collect enough high quality data for structure determination.  This has been 
discussed in the next chapter.  In addition to allowing for the routine collection of static 
structural information of proteins at biologically relevant temperatures as reported above, the 
fine control over transport phenomena coupled with on-chip analysis capabilities offered by 
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these microfluidic platforms could enable a range of other biological studies.  For example, 
precise microfluidic fluid handling could be utilized to enable dynamic structural studies based 
on the addition of various stimuli such as ligands, electrochemical agents, and acid/base to affect 
the pH, or even change temperature.  Such studies have the potential to shed light on structural 
changes associated with protein function in unprecedented ways.  
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Chapter 4
3
 
De novo structure determination of proteins via X-ray 
compatible microfluidic platforms 
 
4.1 Introduction 
Protein structure determination via X-ray diffraction is a critical aspect of structural biology.  
Knowledge of the three dimensional structure of a protein provides insight into the mechanism 
whereby these complex macromolecules function, as well as into potential sites for drug 
targeting
1-3
.  Recent efforts in structural biology have produced not only a large number of 
protein structures, but have helped to lessen bottlenecks 
4,5
, leading to improved, and often 
automated, high throughput methodologies for the cloning, expression, purification, 
crystallization, and X-ray diffraction analysis of novel protein targets 
6-15
.  These approaches 
frequently take advantage of robotics
8-12,14,16
 and/or microfluidics
17-29
.  With these improvements, 
the harvesting and mounting of crystals for X-ray analysis remains the only manual step in the 
structural biology pipeline 
10,30,31
. 
Protein crystallization and structure determination is an intensive multi-step process.  Each of 
the steps of identification and optimization of crystallization conditions, determination of 
appropriate cryoprotection conditions, and examination of heavy atom derivatives or ligand 
binding represents a significant screening effort in the lab coupled with harvesting of individual 
crystals for X-ray diffraction analysis.  However, the scale of these efforts can be hampered both 
by limitations on the quantity of available protein and the difficulties associated with manual 
harvesting of fragile protein crystals. 
                                                     
3
 Part of this work has been submitted in a manuscript to Lab on a Chip and is under review. 
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Current methodologies in protein crystallography rely on collecting structural data from a 
single crystal at cryogenic temperatures to minimize the effects of radiation damage while 
avoiding concerns of crystal-to-crystal variability 
15,32-37
.  This requires harvesting individual 
protein crystals from the crystallization droplet in which they were grown.  However, both the 
physical handling associated with this process and exposure of the crystal to the ambient 
environment have significant potential to damage the crystal 
21,35,38,39
.  Furthermore, the 
cryocooling process has been shown to induce crystal damage, although cryoprotection strategies 
attempt to minimize these effects
15,32,33
.  As a result of this single-crystal paradigm, crystals that 
are not amenable to cryo-crystallography or are highly sensitive to X-ray radiation may prove so 
difficult to work with that they are abandoned in favor of searching for new crystallization 
conditions that do not suffer from these limitations. 
Protein structure determination involves not only the collection of a single diffraction dataset, 
but also generation of phase information. While computational methods such as molecular 
replacement can be used to generate phase information, these strategies cannot be applied to 
novel proteins for which a homologous structure is unavailable
37,40
.  Instead, phase information 
can be obtained experimentally by measuring the anomalous diffraction signal resulting from 
heavy atoms within a protein crystal, either at a single wavelength (single-wavelength anomalous 
diffraction, SAD) or at multiple wavelengths (multiple-wavelength anomalous diffraction, 
MAD) 
34,37
.  Because these anomalous diffraction measurements require the collection of 
symmetry-related pairs of data to observe a small anomalous signal, obtaining data with a high 
signal-to-noise ratio while minimizing radiation-induced damage and crystal non-isomorphism is 
critical.  Historically these stringent requirements have meant that anomalous data must 
effectively be collected from a single protein crystal at cryogenic conditions 
15,37
, with only very 
few examples of anomalous data having been collected from multiple crystals 
34,41-43
. 
Microfluidic approaches for crystallization provide more precise control over the 
composition and kinetic parameters of a crystallization experiment than what is accessible at 
larger scales
17-29
.  However, difficulties associated with harvesting crystals from these devices 
hamper their use.  The crystal harvesting challenge could be mitigated by mounting X-ray 
transparent microfluidic chips directly in the X-ray beam.  Unfortunately, the typical size and 
planar design of microfluidic chips limit rotational freedom and are incompatible with current 
 75 
methods for cryocooling.  Data collection strategies, including how anomalous diffraction data is 
collected, will have to be adjusted to overcome the latter two chip-related challenges. 
The majority of microfluidic chips reported in the literature have been fabricated out of 
relatively thick layers of polydimethylsiloxane (PDMS) and/or glass, which are incompatible 
with the requirements for high quality on-chip X-ray diffraction analysis 
17,23,29,44
.  The designs 
of X-ray compatible microfluidic chips reported in the literature that are based on materials like 
polyimide, poly(methyl methacrylate), and cyclic olefin copolymer (COC) have been relatively 
simple and typically do not take advantage of the high throughput integrated fluid handling 
capabilities characteristic of multi-layer PDMS chips 
18-21,28,45,46
.  In those cases where X-ray 
data was collected from a multi-layer chip, the wells with crystals were punched out from a 
larger chip prior to analysis, a strategy that is not suited for high throughput crystallography 
23,47,48
.  Furthermore, none of the reported examples have been utilized for the collection of 
anomalous data, most likely due to the more stringent signal-to-noise requirements. 
In this chapter, approaches (i) for screening hundreds of crystallization conditions, and 
(ii) strategies to collect high quality structural data using these microfluidic chips, including 
anomalous diffraction data, which is necessary for the phasing and de novo structure 
determination of novel protein targets, are discussed.  The microfluidic chips retain the 
integrated fluid handling capabilities of traditional multi-layer devices necessary for high 
throughput crystallization, while achieving a high level of X-ray transparency.  A large number 
of high quality isomorphic crystals can be grown reproducibly and subsequent mounting of the 
chip in the X-ray beam enables the collection of diffraction data, including anomalous datasets 
for phasing, by merging small wedges of data collected from each of these crystals at room 
temperature.  This approach bypasses concerns associated with crystal damage during handling, 
cryocooling, and radiation exposure.  The approach is validated by solving the structure of a 
novel bacterial phosphonate hydrolase (PhnA) to 2.30 Å using SAD phasing methods that make 
use of data collected on crystals of selenomethionine labeled samples, entirely on-chip at room 
temperature.  As such, this is the first example of an entirely hands-free crystallization and de 
novo structure determination performed within a microfluidic chip. 
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4.2 Materials and methods 
4.2.1 Protein solutions 
Native and Selenomethionine labeled PhnA from Sinorhizobium meliloti was dissolved in 20 
mM HEPES, pH 7.5, at a range of concentrations: 15, 20, 25 and 40 mg/mL.  For screening 
experiments, the 96 condition Hampton Index Screen (Hampton Research) was used and the 
condition I-80 (0.2M ammonium acetate, 0.1M HEPES pH 7.5 and 25% (w/v) PEG 3350) was 
used for further optimization. The crystallization trials were set up with the protein solution at 
1:1 v/v ratio and were incubated at 9°C.  
Traditional microbatch-under-oil crystallization trials were set up combining 2µL each of 
protein and precipitant solutions in a Greiner wellplate (Hampton Research) at 9°C.  These were 
harvested using Mitegen crystal mounts.  
4.2.2 Chip materials and fabrication 
Hybrid microfluidic chips were fabricated out of a thin PDMS (General Electric RTV 650) 
fluid layer bonded to both a molded COC (4 mil, 5013 and 6013, TOPAS Advanced Polymers 
Inc.) control layer and either a 2 mil COC or a 0.5 mil DuraLar (McMaster Carr) substrate.  
Molding of the PDMS fluid layer was done using standard soft lithographic procedures 
22,49
 
while molding of COC control layers was done by hot embossing against an epoxy master 
(Conapoxy FR 1080, 83:100 w/w hardener:epoxy) prepared by soft lithography 
21,50,51
.  Inlet 
holes were drilled using a 750 µm drill bit. The fluid and control layers were bonded using a 
chemical surface treatment 
52
, no bonding to the substrate was necessary.  More details about the 
fabrication procedure can be found in Chapter 2. 
4.2.3 Setup and visualization of crystallization experiments  
Crystallization experiments were set up and visualized using either a stereomicroscope 
(Leica, MZ12.5) with an attached digital camera (Leica, DFC295) operated using Leica 
Application Suite software or a computer controlled imaging system comprised of an optical 
microscope (Leica Z16 APO) equipped with an auto-zoom lens (Leica 10447176), a digital 
camera (Leica DFC280), and a motorized x-y stage (Semprex KL66) controlled by Image Pro 
Plus (Media Cybernetics).  For visualization of protein crystals, images were occasionally taken 
with the use of a cross-polarizer.   
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Traditional microbatch-under-oil crystallization trials were set up combining 2 µL each of 
protein and precipitant solutions in a Greiner wellplate (Hampton Research) at room 
temperature.  These were harvested using Mitegen crystal mounts.  Incubation of array chip 
screening experiments for PhnA was performed in a dark box at room temperature.   
4.2.4 On-chip X-ray data collection 
Samples were mounted on a modified magnetic goniometer mount (Hampton Research) with 
an attached metal tube into which a slit was cut and set-screw was used for securing samples.  
Data collection was performed at room temperature.   
Synchrotron diffraction experiments were carried out at the LS-CAT (Life Sciences 
Collaborative Access Team) facility at the APS (Advanced Photon Source), Argonne National 
Lab in Lemont, IL.  Beamlines 21ID-F and G were used for most of the data collection. Sample-
to-detector distances were varied between 150 to 300 mm based on the quality of the crystal 
present in the chips.  Typical data collection was done using a 1° oscillation with a 1 s exposure 
at an X-ray energy of 12.7 keV (λ = 0.979 Å).  For merging slices of data from multiple crystals, 
10° of data (-5° to +5° from the normal) was collected from various crystals in the device and an 
optimal subset of the frames was subsequently merged to obtain a complete dataset.  For 
anomalous datasets, two datasets were collected, one straight on (5° of data, 0° to +5° from the 
normal) and the other after rotating the chip by 180° (5° of data, -5° to 0° from the normal) to 
give a total of 10° of data. 
Analysis of X-ray diffraction data collected at the synchrotron was performed using 
HKL2000 software for indexing, refinement, integration, and scaling (HKL Research Inc.).
53
  
The resolution range of the data was established based on the resolution shell at which I/σ fell 
above 2.0.  Subsequent processing of crystallography datasets was done using the CCP4 suite of 
programs.
54,55
  MTZ files were generated using Scalepack2mtz from the CCP4 software package.  
Anomalous data first scaled using SCALEPACK in HKL2000 with the "Scale Anomalous" flag 
and truncated at Rmerge ≤ 0.25 (resolution 2.75 Å) for obtaining phase information.  The scaling 
data was extended to Rmerge ≤ 0.5 (resolution 2.31 Å) and used for building the complete model.  
Subsequent processing of crystallography datasets was done using the CCP4 suite of programs.  
Electron density maps were generated by Phenix and images were generated using PyMOL.
56
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The phase problem was solved using the Phenix.Autosol wizard in Phenix
57
 to locate the 
selenium atoms of the selenomethionine residues, followed by heavy atom refinement 
(FOM=0.394).  The initial phases were further improved by density modification in the 
Phenix.Autosol wizard and a model was built with the Phenix.Autobuild wizard with 72% 
completeness.  This was used as a starting model in the Phenix.Autobuild wizard for the 2.11 Å 
resolution experimental data and a model that was 79% complete was obtained.  The model was 
further extended to 97% completeness using ARP/wARP
54
 and refined using Phenix.Refine 
wizard to Rwork of 0.176 and Rfree of 0.211.   
4.3 Results and discussion 
In the subsequent sections, I will first briefly discuss the X-ray transparent architecture 
utilized in these crystallization platforms.  I then apply these X-ray transparent microfluidic array 
chips to the screening and optimization of crystallization conditions of PhnA, a novel bacterial 
hydrolase. Here I validate the utility of these chips for both cryogenic and room temperature on-
chip X-ray data collection.  In particular I demonstrate the ability of these chips to reproducibly 
generate a large number of crystals without suffering from variations in crystal quality or non-
isomorphism.  Finally, I discuss the de novo structure determination of PhnA utilizing a 
completely on-chip approach and discuss the potential for extending this method to other novel 
protein targets. 
4.3.1 Design and fabrication of X-ray compatible microfluidic crystallization array chips 
Considerations that must be addressed when designing an X-ray transparent chip are (i) X-
ray attenuation and scattering from the chip itself, and (ii) the ratio of signal-to-noise resulting 
from the diffraction from a protein crystal as compared to the level of background scatter.  The 
first point can be addressed through careful consideration of the composition, properties, and 
thickness of the materials used, while the second point asks for consideration of the relative path 
length for diffraction through the crystal compared to the path length through the device 
materials. 
The integration of pneumatic valves on the chips is essential to enable active control for 
complex microfluidic fluid handling operations for formulation of crystallization trials, and 
typically requires the use of a flexible elastomer like PDMS 
49,58,59
.  Actuate-to-open valves were  
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fabricated by aligning a control layer made from COC, which defines the location of valves, with 
 80 
a fluid layer made from PDMS, which defines the location of fluid channels and compartments 
(Figure 26a).  This hybrid structure enables valve actuation while leaving only a thin PDMS 
valve membrane in the X-ray path, regardless of the total height of the fluid layer.  Additional 
window-like structures present in the COC control layer further decouple the device material 
thickness from feature height, thus enabling the use of thicker control layers to provide device  
stability without impacting performance.  This device structure is then placed onto a thin film of 
either COC or the polyethylene terepthalate-based DuraLar to seal the device.  A typical device 
used here requires the X-rays to pass through a 75-µm COC control layer, a 20-µm PDMS 
membrane, and either a 50-µm COC substrate or a 12-µm DuraLar substrate, resulting in the 
transmission of 75-78% of the incident X-rays at an energy of 12.4 keV (λ = 1 Å). 
The device materials also produce an X-ray scatter ring (Figure 26d) that contributes to the 
level of background noise.  This ring can be minimized by decreasing the thickness of the 
materials present.  Furthermore, the scatter appears at a location where it does not affect the 
signals needed for high resolution structure determination (q ≈ 0.161 Å-1 (7.5 Å) for PDMS and q 
≈ 0.232 Å-1 (5.2 Å) for COC).  For example, examination of on-chip diffraction data from a 
~100-µm thick PhNA crystal grown on-chip shows that diffraction signals are clearly observable 
over the background resulting from the chip materials, even at the peak of the observed 
scattering ring (Figure 26d). 
I fabricated 24- and 96-well microfluidic array chips with automated fluid handling 
capabilities for use in screening crystallization conditions, as well as in subsequent structure 
determination (See Chapter 2 for further details).  These chips utilize actuate-to-open valves to 
create densely packed arrays of microfluidic wells 
58,59
.  A single well on the chip consists of two 
sets of half-wells, each loaded respectively with protein and precipitant solutions.  For a typical 
50-µm chamber height this corresponds to ~50 nL per half-well and thus a total chip volume of 
~1.4 µL for a 24-well chip and ~5.6 µL for a 96-well chip.  This chip design can be configured 
such that the ratio of protein-to-precipitant varies for each precipitant solution tested (screening 
phase, Figure 27), or in a manner that all wells are identical (for X-ray data collection) 
composition.  The individual compositions are formulated using three sets of valves: for 
introducing the protein (shown in blue), for introducing the precipitant (green, Figure 27), and 
for mixing two adjacent half-wells (pink, Figure 27).  Solution droplets are pipetted over inlets, 
and then the solution is pulled into the rows or columns of wells by actuation of the appropriate 
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set of valves.  Subsequent actuation of the mixing valves between adjacent half-wells creates the 
individual crystallization compositions.  A detailed description of the chip operation can be 
found in Chapter 2. 
4.3.2 On-Chip crystallization screening and structure determination 
First, I validated my approach to crystallization screening by comparing the results obtained 
in these microfluidic chips with those for traditional microbatch-under-oil in a wellplate using 
the soluble protein lysozyme and the 50-condition Crystal Screen kit (Hampton Research) at 
room temperature (Chapter 3).   
 
I pursued the de novo structure determination of phosphonacetate hydrolase (PhnA) from 
Sinorhizobium meliloti.  The first step in structure determination of a new protein is screening 
against various potential crystallization reagents. Screening was performed using the 96-
condition Index Screen (Hampton Research) on a 96-well chip where the ratio of protein-to-
precipitant was varied (4:1 to 1:4, Figure 27).  Each 96-well screening chip allows 12 different 
precipitants to be screened against a single protein solution.  A total of eight chips were used for 
screening the entire Index Screen.  Each chip requires just 6 µL of protein and 2 µL of each 
precipitant solution to screen a total of 96 different conditions.  Since the chamber volume ratio 
is varied along the vertical (Figure 27a,b), these chips are screening each of these 12 conditions 
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over 8 different protein-to-precipitant ratios, effectively increasing the experimental range of the 
experiment.  This type of screen, varying the protein-to-precipitant ratio, can be set up 
automatically on these microfluidic chips, while it would be much harder to implement at the 
traditional well plate scale where each condition would need to be set up independently.  Each of 
these chips takes < 5 minutes to set up, thus enabling a large number of crystallization trials to be 
set up in a high throughput fashion.  The microfluidic chips are extremely simple to set up, 
requiring only a pipette to meter the protein and precipitant solutions and a vacuum pump with a 
Teflon-tubing based connector to fill in the solutions into the chip 
60
. 
Screening of a selenomethionine (SeMet) derivative of PhnA (10mg/mL) with the Index 
Screen gave hits in 21 out of the 96 conditions (Figure 28, Table 4), in comparison to just 3 hits 
obtained off-chip using traditional methods.  The hits obtained in the first round of screening 
produced showers of tiny crystals, which diffracted to 3Å due to small size of the crystals 
resulting in poor signal-to-noise (Figures 3b,c).  The condition I-80 produced the best crystals in 
the first round of screening and all subsequent optimization was done on that condition only.  
The next series of optimization was done with respect to the protein concentration (15, 20 and 25 
mg/mL) as well as device geometry.  In the first round of screening it was observed that the 
thickness of the crystals was limited by the height of the microfluidic chamber.  This in turn 
meant that the X-ray beam would pass through more of the chip material than crystal, affecting 
the signal-to-noise quality of the resultant data. Consequently, in subsequent designs the height 
of the fluid layer was increased to 100 µm to allow the crystals to grow thicker in the direction of 
the X-ray beam and improve signal-to-noise.  The mixing time between the protein and 
precipitant was also increased (from 20 minutes to 60 minutes) to allow better mixing.  A longer  
 
Table 4. Summary of crystallization results of a microfluidic screen of 25 mg/mL PhnA in 20mM HEPES at pH 7.5 
against the 96-condition Hampton index screen. 
Condition 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1-16 –a – – – – – – – – – – – – – – – 
17-32 – – – – – – – – – – – – – – – – 
33-48 – – – – – – – – – +b – – – – + – 
49-64 – – – – – + – – – – – – – – – – 
65-80 – – – – – + + + + – – – – + + + 
81-96 + – – – – + + + + + + + – + + + 
a– No crystals observed. b+ Crystals observed 
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incubation time for the crystallization trials was achieved by equilibrating the finished 
crystallization trials within a petri dish with a vial of the precipitant solution, thus preventing 
dehydration of the chip.  The highest quality crystals were grown using a higher protein 
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concentration (20 mg/mL), taller fluid channels and longer mixing time (Figure 28c).   
4.3.3 On-chip phasing via single wavelength anomalous diffraction (SAD) 
For novel proteins, once high quality crystals have been grown, obtaining phase information 
needed to solve the protein structure is one of the key remaining bottlenecks.  This is particularly 
true for targets with low sequence identity to proteins of known structure, where the addition of 
structural knowledge could provide a wealth of information 
61
.  The difficulties associated with 
obtaining phase information from anomalous diffraction methods such as SAD center around the 
need to collect a large amount of high quality data that is unaffected by either radiation damage 
or crystal-to-crystal variation 
15,37
.  Because of these limitations, anomalous data collection has 
mostly been limited to traditional single-crystal studies at cryogenic temperatures.  Furthermore, 
the need to observe very small differences in a large signal has thus far precluded the on-chip 
collection of anomalous data from crystals grown within microfluidic chips. 
Table 5. Summary of crystallographic statistics for PhnA crystals grown on-chip 
Parameter SeMet [a] 
Data Collection 
Unit Cell Dimensions a = b = 113.19 Å c = 73.87 Å 
Space Group P43212 
Total Observations  
Unique Observations 
412,491  
28,002 
Resolution 50 Å – 2.11 Å 
Rsym 0.111 (0.508) 
Mosaicity 0.04o 
Redundancy 7.9 (6.7) 
Figure of Merit 0.394 
Completeness 99.8% (99.8%) 
I/σ 15.4 (6.6) 
# of Frames 188 
Refinement 
R (Rfree) 0.176 (0.211) 
Ramachandran Statistics 
Most Favored 95.61% (392) 
Allowed 2.68% (11) 
Disallowed 1.71% (7) 
[a] Selenomethionine derivative of PhnA for phasing. Reported values are for all hkls.  Values shown in parenthesis represent the value for the 
highest resolution shell except where indicated.  For the Ramachandran statistics the number in parenthesis indicates the number of residues in a 
given region.  R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and Rfree is the R value for a test set of reflections consisting of a random 5% of the diffraction 
data not used in refinement.  Rsym = Σ |(Ii - <Ii> | Σ Ii where Ii = intensity of the i
th reflection and <Ii> = mean intensity. 
In a strategy similar to what was applied for the collection of room temperature diffraction 
data for lysozyme, small wedges of data were collected from 86 PhnA crystals.  However, 
because anomalous diffraction experiments require a comparison of the diffraction signal from  
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symmetry-related pairs of data, an inverse-beam mode of data collection was used.  The crystal  
was rotated 180° after the collection of 5 frames (1s, 1° oscillation) to collect data on the 
corresponding Bijvoet pairs.  This strategy helped to mitigate the effects of radiation damage due 
to extended exposure to the X-ray beam, and maintained crystal quality during data collection of 
symmetry-related signals. 
Anomalous diffraction experiments require the comparison of the diffraction signals from 
symmetry-related pairs of data, therefore, an inverse-beam mode of data collection was used.  
The crystal was rotated 180° after the collection of 5 frames (1 second, 1° oscillation, 19 
crystals) to collect data on the corresponding Bijvoet pairs.  This strategy helped to minimize 
radiation damage due to extended exposure to the X-ray beam, and maintain crystal quality 
during data collection of symmetry-related signals.  SeMet PhnA crystals diffracted to a  
resolution limit of 1.80Å.  These small wedges of data were merged to obtain a complete dataset 
and then used to solve the structure of PhnA to a resolution of 2.11Å using only on-chip data 
(Table 5).  As seen in Figure 29c, the anomalous signal is clearly observed beyond 2.75Å, 
indicated by the difference in χ2 for Friedel mates treated as equivalent and independent.  Other 
anomalous indicators including Rmerge and <ΔF
±>/<σ(F)> showed similar patterns (data not 
shown). 
For comparison, PhnA crystals were also grown in a traditional microbatch setup and 
analyzed using traditional single-crystal cryo-crystallographic techniques.  As in the case of 
lysozyme, the single crystal analyzed via cryogenic methods diffracted to a higher resolution 
(1.70 Å vs. 2.11 Å), a difference that is probably due to the difference in crystal size.  Both 
datasets were very complete, despite the lack of orientational control available in collecting small 
wedges of data.  Variations in Rsym were within a range typical for good diffraction data, and I/σ 
and structural refinement parameters such as R/Rfree and Ramachandran statistics are comparable 
for both cases.  As in the case of lysozyme, analysis of mosaicity shows again that on-chip 
analysis at room temperature results in a nearly one order of magnitude decrease as compared to 
single-crystal cryogenic data.  The two structures matched to an RMSD < 0.4 Å when aligned in 
PyMOL 
56
.  The primary aim  of this study is to ascertain that high quality structural information 
can be obtained from crystals grown on the chip and detailed analysis of the structure and 
function of this protein is beyond the scope of this work. 
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4.4 Conclusions 
In summary, this is the first example of an entirely hands-free crystallization and de novo 
structure determination for a novel protein target in a microfluidic chip.  This achievement was 
enabled by the coupling of novel approaches for the construction of X-ray compatible multi-
layer microfluidic chips with non-traditional strategies for the collection of high quality on-chip 
X-ray diffraction data at room temperature.  The fine control over transport phenomena achieved 
within microfluidic chips facilitates the reproducible growth of a large number of isomorphous 
crystals, allowing the collection and merging of small sets of diffraction data from many crystals 
thereby avoiding the effects of radiation damage associated with room temperature data 
collection.  I validated this strategy for the on-chip collection of single-wavelength anomalous 
diffraction data for PhnA, a novel bacterial phosphonate hydrolase, resulting in a structure to a 
resolution of 2.11 Å. 
The current paradigm in structural biology has been focused on the collection of X-ray 
diffraction data under cryogenic conditions from a single crystal.  Because of the challenges and 
variability introduced by the manual harvesting of crystals, all of the data needed would ideally 
be collected from a single crystal to avoid challenges with crystal-to-crystal variability 
15,32-37
.  
Unfortunately these data collection strategies have tended to preclude the use of novel 
crystallization platforms such as microfluidic chips that are less compatible with cryogenic data 
collection.   Moreover, the traditional approaches lead to wasted time and material in search of 
crystal forms that are sufficiently robust to withstand X-ray radiation damage.  The ability of my 
microfluidic platforms to generate a large number of reproducible crystals from which high 
quality on-chip X-ray data can be collected at room temperature has the potential to shift this 
paradigm, particularly in the case of recalcitrant targets.  One can envision overcoming the 
challenge of collecting anomalous data from crystals that degrade in quality after only a few 
frames of data are taken by collecting only a single set of symmetry-paired frames from a large 
number of crystals.  Efforts on extending this approach to other novel protein targets are 
currently underway. 
Our microfluidic approach is especially directed towards instances where traditional 
methods yield protein crystals that are too small or fragile, because it eliminates crucial manual 
steps of crystal harvesting and mounting that are often the principal obstacles in obtaining good 
 88 
quality diffraction data.  Our approach only requiring a vacuum pump and microscope, while 
expending minimal amounts of valuable protein and reagents, provides researchers, especially 
those working on membrane proteins, the capabilities to successfully screen a wide variety of 
conditions in crystallization space.  This ability to screen at nanoliter volumes per condition is 
typically only available to well-funded, specialized research laboratories that can afford 
crystallization robots.  Our technology enables the opportunity for researchers to re-visit projects 
where structure determination was abandoned due to the inability of the protein crystals to 
survive manual harvesting steps, survive cryo-cooling, or radiation damage, and successfully 
couple them. The platform reported here potentially can also be used to facilitate dynamic 
structural studies that shed light on the change in structure during protein function, ranging from 
proteins that respond to stimuli such as light, pH, or the presence of ligands, to those that respond 
to temperature or electrical changes, thus opening up opportunity for a large variety of 
previously elusive biological studies.  
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Chapter 5 
Microseeding approaches in crystallization using 
microfluidic platforms 
5.1 Introduction 
Advances in structural genomics over the past decade have greatly succeeded in streamlining 
the entire structure determination pipeline process for proteins.  Massive undertakings like the 
Protein Structure Initiative (PSI) are trying to replicate the success the Genome project had in 
sequencing, in unearthing the structures of as many novel proteins as possible
1-3
.  Even with a 
huge financial backing, great improvement in protein expression and purification methods, and 
the advent of high throughput screening the progress has been excruciatingly slow.  There are 
nearly 600,000 high resolution small molecule crystallographic structures deposited in the 
Cambridge Crystallographic Data Center (CCDC) as of January 2011, while the number of 
protein structures deposited in the protein data bank (PDB) is relatively fewer (82224 as of 
March 2013).  This is because of the difficulty associated in obtaining high diffraction quality 
crystals from protein solutions, and has led to researchers looking into various methods to 
increase the probability of obtaining crystals as well as improving crystal quality.  Seeding is 
amongst the most dominant of these techniques and has proved extremely successful in 
unraveling the structure of a large number of proteins
4-6
. 
Protein crystallization is more an art than a science.  The fact is that the optimal conditions 
which lead to nucleation of crystals are not ideal for their subsequent growth.  Generation of 
nuclei is possible when the crystallization solution is supersaturated, while growth of crystals is  
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found to occur at much lower supersaturation levels without further nucleation
4,5
.  It is ideal to 
separate the nucleation and growth stages of a crystallization trial so as to enable both processes 
to occur completely (Figure 30).  Seeding is an effective technique to separate the nucleation and 
growth phases of protein crystallization.  In this method, protein crystals that have been 
previously grown are used as seeds and introduced into fresh crystallization trials at lower levels 
of supersaturation.  Based on the size of the seeds, the seeding method can be classified into two 
classes
4
: 
(a) Microseeding: transfer of seeds that are so small that they cannot be distinguished 
individually 
(b) Macroseeding: transfer of a whole, single crystal, usually 5-50 µm in size 
It is also not necessary that the same protein be used to seed for its own growth trials, cross 
seeding is also practiced where seeds from a different family of proteins are introduced into trials 
with a different protein (heterogeneous seeding).  Also, it is not necessary that protein crystals 
are always used as seeds.  Heterogeneous seeding is a technique where in other materials like 
minerals, crushed animal hairs, porous nucleants and thin films etc. have been used to 
successfully induce crystal nucleation
5
.  
Preparation of the seeds for implementation of seeding techniques is a labor intensive 
process.  Macroseeding, also called seed transfer, requires tedious transfer of a parent crystal 
through multiple washes before it can be used for seeding.  It is mostly used in cases where a 
great increase in the size of the crystal is needed.  In most cases however, a whole crystal is not 
required.  In microseeding, submicroscopic crystals, or seeds, are prepared by pulverizing the 
existing crystals to prepare seedstock, and then diluting these seedstocks for seeding.  Streak 
seeding is a variation of this method, where an animal whisker is stroked against a protein crystal 
and picks up tiny fragments of the crystal and is then run through a crystallization drop.  The 
problem with microseeding methods is that it is difficult to control the specific amount of seeds 
in a trial.  One of the latest seeding techniques is microseed matrix screening
7
, in which 
microseeds from the initial nucleation step are subsequently seeded into various different 
conditions to induce crystal growth (Figure 31).   
Conventional methods for crystallizing proteins (such as vapor diffusion, microbatch) have 
been very successful in determining the structures of proteins with disparate topologies and  
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subunit compositions, and from different phyla and membrane types
8
.  These methods have their 
advantages for many proteins and structural biology laboratories such as ease of set up and well-
studied experimental protocols.  The reason why seeding is not popular yet, is that it has not been 
able to integrate well into current high throughput crystallization platforms. 
Seeding techniques in the past few decades have been focused on manually extracting seeds 
using horse or cat hairs and transferring them to crystallization drops.  However, recently there 
have been attempts to automate the process with some success.  Microseeding is one of the most 
powerful tools for protein crystallization, but it is rarely used due to the complexity of the 
procedure and the skill required
4
.  It is particularly useful in cases of membrane protein 
crystallization, specifically the in surfo method.  It is one of the best methods to accelerate 
identification and optimization of crystallization conditions for the in surfo approach.  Many 
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attempts to simplify the procedure have been reported
9-13
, however they are still labor intensive 
and have not significantly reduced the setup time of the microseeding method. 
Taking advantage of the two-step process of crystal formation, crystal nucleation and growth, 
microseeding transfers a submicroscopic crystal from a condition where supersaturation is high 
to one where the supersaturation is in the metastable zone which aids the growth of crystals 
(Figure 30,2)
14
.  Considerable research has been done to study the kinetics and dynamics of 
nucleation and crystal growth, along with many approaches to decouple the nucleation and 
growth processes to enhance the rate of crystallization success,
15-24
 including a microfluidic 
droplet-based approach
25
.  During the initial screening for crystallization conditions, often 
conditions are identified that give rise to microcrystals, spherulites, fine needles, or irregular 
poorly formed crystals (Figure 32).  Microseed matrix screening is a procedure where such 
microcrystals or spherulites are crushed to form microseeds that then are used to re-screen the 
initial matrix as nuclei for conditions that support ordered crystal growth
10,26-28
.  The best 
conditions from the resulting screen are harvested and the process is iterated to produce 
diffraction-quality crystals.  Microseed matrix screening has been used successfully in cases 
where the best conditions for crystal growth without seeding lead to precipitation,
10
 to accelerate 
crystal growth of proteins complexed with hydrolysable substrates where the absence of seeding 
resulted in a hydrolyzed substrate,
14
 to crystallize antibody-antigen complexes,
11
 and many more 
cases
29-32
 . 
 
D’Arcy et al. have reported an automated matrix microseeding method wherein seeding has 
been integrated into the screening method
13
.  This method involves adding the microseeds during 
the screening phase using a standard crystallization robot and has provided some success in 
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increasing hits in the initial screening runs.  However this method is a departure from traditional 
screening philosophy, where seeds are grown independently in a supersaturated solution, so that 
they remain out of solution, otherwise they are expected to re-equilibrate and dissolve.  To 
implement this technique in a high throughput manner requires the use of crystallization robots 
that are at present not accessible to a lot of structural biology laboratories.  There is a distinct 
need for a low cost technology that can allow setting up of seeding trials in a high throughput 
manner. 
Many efforts to simplify microseeding and automate the process have been successfully 
implemented for various proteins
12,26-28,33-35
.  Microseeding robots pre-mix the protein, 
precipitant and microseed solution during crystallization set up.
28
  Femtosecond laser ablation 
has been used to eject crystal fragments that serve as seed in the same crystallization drop.
33
  
Acoustic matrix microseeding utilizes acoustic waves to deliver nanoliter volumes of seed 
suspension into protein drops.
35
  Despite the promise of these improved crystallization success 
with microseeding, it remains an under-utilized tool and is often chosen as the last resort when 
all other attempts to grow high quality crystals have failed.  The procedure of making microseed 
stock solutions is the easy part, but introducing the microseed to the crystallization droplet 
requires skill and experience when performed manually. Microseeding robots can perform 
routine microseed matrix screening but are not widely available to biochemical labs that would 
benefit from using this technique.  
We recently have succeeded in simplifying the process of microseeding using the X-ray 
transparent array chips described earlier.  Our approach has the strengths of being simple, easily 
accessible to researchers of any skill level, and incorporates a time variable for seeding that is 
absent even in the most recent robotic microseeding machines. 
5.2 Materials and methods 
5.2.1 Protein purification 
Photoactive yellow protein (PYP) from E. Halophila was expressed as an exogenous product 
in E. Coli and then purified to give holo-PYP that was used for crystallization trials.  The protein 
was supplied by Dr. Marius Schmidt from the University of Wisconsin, Milwaukee.  Following 
is the protocol for the protein purification: 
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Day 1: 5mL ampicillin containing LB media was inoculated in a disposable culture tube with a 
single colony from E.halophila BN9626 plate.  It was then grown overnight (~10hrs) with 
shaking at 37°C.  
Day 2: 100mL of ampicillin containing LB media was inoculated in a 250mL Baffle flask with 
the above 5mL culture (1 in 20 dilution).  It was subsequently grown overnight with shaking at 
37°C.  
Day 3: 4 × 1L each of ampicillin containing LB media was inoculated in 2L baffle flasks with 
20mL each of the 100mL overnight culture (1 in 50 dilution).  It was grown with shaking at 37°C 
until an OD600 (optical density measured at a wavelength of 600 nm) of 0.6 – 0.8 is reached.  At 
optimum OD600 the flasks were removed from the shaker and kept on ice for 15 minutes to stop 
growth. In the meantime, the shaker was set at 16°C.  The 4 × 1L cultures were induced with 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) to a final concentration of 1mM.  The induction 
was carried out with shaking at 16°C for 20 - 24hrs.  
Day 4: The cells were harvested by centrifugation at 8,000 g for 25 min at 4°C (JA-10 rotor, 
500mL bottles).  The cells were then resuspended in ~80mL Lysis Buffer and stirred at 4°C for 
15min.  Lysozyme (200µg/mL) and 2 aliquots (500µL) of protease inhibitors cocktail were 
added just before sonication at 70% amplitude for 1min (5 – 6 times).  To clarify the cell debris, 
after sonication, the mixture was centrifuged at 22,000 rpm for 20min at 4°C (JA - 25.50 rotors, 
50mL tubes.  The supernatant was pooled into a beaker and activated pCA anhydride was slowly 
added while stirring.  The beaker was stirred overnight at 4°C.  
Day 5: The column was packed with 10mL of pre-charged IMAC Ni2+ resin (take 20mL since 
resin stored in 50% v/v 20% ethanol).  Let the resin settle by adding dH2O (de-ionized water) at 
regular intervals (do not let the resin dry out).  The flow adapter was washed with dH2O using a 
syringe, making sure there was no air bubbles in the tubing.  The flow adapter was attached to 
the peristaltic pump and the pump was run with dH2O till there were no air bubbles in the tubing.  
While running the pump, the flow adapter remained attached to the column to make sure there 
were no air bubbles at the adapter-resin interface.  
The column was equilibrated with Lysis buffer (100mL).  In the meantime, the protein-pCA 
mixture was centrifuged at 20,000 rpm for 25min (JA-25.50 rotor, 50mL tubes) to get rid of the 
excess pCA.  The supernatant was pooled into a fresh beaker and labeled as LOAD.  The 
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supernatant was loaded on the column at a steady flow rate.  An empty beaker was labeled as 
FLOW THROUGH (F.T.) and the flow through was collected in it. 15µL of LOAD was 
collected for SDS-PAGE analysis.  After loading the column, it was washed with Lysis buffer 
(50mL) followed by Wash buffer (50mL) and the flow through was collected in a fresh beaker 
labeled as RINSE.  The protein was eluted with Elution buffer and the elute was collected in a 
fresh beaker.  After elution, the column and tubings were washed with 20% ethanol and dH2O.  
15µL of F.T., RINSE and ELUTE were collected for SDS-PAGE analysis.  
The purification was analyzed by running a SDS-PAGE gel. The ELUTE was dialyzed 
against Overnight Dialysis buffer -1 in 2L graduated cylinder to remove excess Imidazole.  
Day 6: The ELUTE is concentrated to ~ 10mL in Millipore Amicon 10K tubes.  The protein 
concentration was checked using spectrophotometer and the Abs 280nm/446nm ratio was 
recorded.  15µL of concentrated ELUTE was collected for SDS-PAGE analysis.  Enterokinase 
was added to the concentrated ELUTE and rocked overnight (16 hours) at room temperature to 
cleave the His tag.  
Day 7: The Ni2+ affinity column was washed with dH2O and equilibrated with Lysis buffer.  The 
elute+enterokinase mixture was loaded and the F.T. was collected in a fresh beaker.  15µL of cut 
concentrated ELUTE was collected for SDS-PAGE analysis.  Ideally, all the cut PYP will flow 
through while the His tag fragments and uncut PYP will cling to the column.  The column was 
washed with the lysis and wash buffers and the flow through were collected as WASH.  The 
column was further washed with Elution buffer to get rid of the uncut PYP from the column.  
15µL of F.T. and WASH were collected respectively for SDS-PAGE analysis. A SDS-PAGE gel 
was run to analyze the extent of cleavage.  The PYP was concentrated to ~ 1mL in Millipore 
Amicon 10K tubes for Ion-Exchange Chromatography next day.  
Day 8: The Ion-Exchange Chromatography was run using AKTA FPLC system.  The tubings 
were washed with Buffer A (20mM Tris at pH 8.0) and Buffer B (20mM Tris, 1M NaCl at pH 
8.0) to get rid of any air bubbles.  The column was washed with Buffer A for 10 – 15min and the 
loop was washed with Buffer A as well.   
The tubes that appeared yellow were labeled and absorption spectrum for each of them was 
measured.  The fractions corresponding to the first peak in the elution profile were pooled.  The 
fractions corresponding the shoulders of the peak were avoided.  The second peak may represent 
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apo-PYP i.e. without the chromophore.  This explains the absorption spectrum for the fractions 
representing the second peak where the Abs 280nm/ 446nm is relatively higher compared to the 
first peak fractions.  
If the peak separation is bad and the majority of protein still exists as holo and apo- pyp 
mixture, another ATKA can be run with smaller fraction volume and longer gradient to improve 
the resolution.  
Day 9: The pooled fractions were concentrated to 15 – 30 mg/mL in Millipore Amicon 10K 
tubes.  They were dialyzed overnight against the final storage buffer at 4°C.  The final protein 
was then filter sterilized.  Aliquots of 20 µL aliquots were flash frozen in liquid nitrogen and 
store at -80°C. 
5.2.2 Protein crystallization 
Vapor diffusion (hanging drop) trials were set up for crystallizing PYP, the precipitant used 
was 2.8M ammonium sulfate and 0.9M sodium chloride at pH 7.0
36
.  Trials were setup at room 
temperature.  Crystals were obtained in the P63 space group within a week.  The crystals 
however grew in bunches (Figure 33) and single, isolated crystals were not obtained.  This is a 
well-known problem in crystallizing PYP.  The crystal clusters were harvested and used for 
microseed preparation.  
5.2.3 Microseed preparation 
Microseed stock solution was prepared using a tissue homogenizer and seeds harvested from 
hanging drop experiments described in section 2.2.  Crystals were harvested from the hanging 
drop and placed carefully in the glass tube of the homogenizer.  Seed stock was made in the 
same condition that produced crystals (Ammonium sulfate, pH 7.0 and NaCl), at a 20% higher 
concentration than what induced crystallization so that the crystals do not dissolve.  The crystals 
were then pulverized using the homogenizer
34,37
, until no crystal fragments could be seen in the 
glass tube under the microscope.  This formulation became the stock solution for the PYP seeds 
from which serial dilutions were made with the stock solution.  The dilutions made were 1:1, 1:2, 
1:10, 1:100, 1:1000 and 1:10000, with each successive dilution containing fewer and fewer 
nuclei. Figure 34 describes the procedure of making seed stock solutions.  
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5.2.4 Microfluidic chip fabrication 
Fabrication of the microfluidic chips used for microseeding was carried out using the 
modified approach which eliminates hot embossing.  Briefly, PDMS mixed with the crosslinker 
in ratios of 5:1 and 15:1 was spun onto control layer (CL) and fluid layer (FL) silicon masters.  A 
thin sheet of 2 mil COC was plasma bonded onto the partially cured PDMS on the CL master 
and baked for complete adhesion.  After baking at 60ºC for 1 hour, the COC sheet with the CL 
was peeled off, and aligned over the FL master.  This combined assembly was baked at 60ºC for 
4 hours to allow the PDMS layers of different ratios to bond together.  Finally the combined 
assembly was peeled of the FL master, holes were drilled for the CL and FL inlets, and the chip 
was placed on a flat COC substrate to complete the assembly. 
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5.2.5 Setting up and visualization of seeding trials 
Reagents were filled in the microfluidic chip using a vacuum pump coupled with a modified 
manifold with Teflon tubes and PDMS blocks to apply vacuum on the inlets.  The various 
reagent solutions (protein, precipitant seed stock etc.) were pipetted onto the respective inlet 
holes and sucked in through vacuum.  The solutions in the adjacent chambers were mixed using 
vacuum actuated valves between the chambers.  After setting up of the trials, the chips were 
placed in sealed petri-dishes and incubated at room temperature.   
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Visualization and setup of the crystallization experiments were done with the help of a 
stereomicroscope (Leica, MZ12.5) with an attached digital camera (Leica, DFC295) operated 
using Leica Application Suite software or a computer controlled imaging system comprised of an 
optical microscope (Leica Z16 APO) equipped with an auto-zoom lens (Leica 10447176), a 
digital camera (Leica DFC280), and a motorized x-y stage (Semprex KL66) controlled by Image 
Pro Plus (Media Cybernetics).  Images were periodically taken with the help of a cross-polarizer.  
5.3 Results and discussion 
Seeding during crystallization trials is a technique to improve the chances of getting 
diffraction quality crystals, when normal crystallization methods are yielding poor results.  Here, 
we demonstrate how we can use the array chip developed for screening and on-chip structure 
determination for microseeding trials.   
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5.3.1 Microfluidic chip for seeding trials 
The microfluidic chip described in the previous chapters is used as is for the microseeding 
trials.  The advantage in using the same chip is that the procedure for fabrication and setting up 
trials was already well laid out and we could modify it to use it for seeding trials.  The seedstock 
solution was prepared from crystals of PYP grown in hanging drop trials as described in the 
Materials and Methods section.  In traditional seeding experiments, the seed is physically 
introduced by adding a hair or whisker with seeds already present on them and allowing crystals 
to grow along the hair.  However in order to automate the seeding process and make it more user 
friendly, we had to devise a way to introduce seeds into the microfluidic wells.  The array chips 
we are using here have two half wells in each crystallization chamber on-chip; one houses the 
protein and the other the precipitant.  Here we have three solutions to fill into the chip, the 
protein, precipitant, and, the seeding solution.  We could have added a third chamber to house 
the seeding solution, but that would have introduced complexity into the device in terms of 
filling and inducing mixing.  This is something to add when we are looking to optimize the 
seeding process on-chip, but for proof of principle studies, we wanted to utilize an identical chip 
to see whether seeding was possible or not. 
The 24-well array chip used here has two sets of inlets, one for the protein and one for the 
precipitant, and there are three sets of solutions we need to fill in.  There are three combinations 
we tried on-chip, first adding the seed solution with the precipitant and adding it to the 
precipitant inlet and adding the protein solution as before through the protein inlet (Figure 35).  
A dilution series of seedstock solution was prepared (see Materials and Methods) with each 
series containing different number of nuclei, and each of the six inlet lines contained a different 
dilution of the seed stock solution.  The second combination (Figure 36) we tried was adding the 
seed solution along with the protein solution and the precipitant solution was added as is in the 
precipitant inlets.  This strategy meant that we needed a whole chip for each dilution we wanted 
to screen.  To get around this, we can also switch the protein and precipitant filling inlet, and fill 
the same protein with different dilution series of seed stock in the six (usual) precipitant inlets 
and fill the precipitant through the (usual) protein inlet.  The third combination (Figure 37) 
involves premixing the protein and precipitant and adding them through the protein inlet and  
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adding the seed solution (in dilution series) through the precipitant inlets.  On close inspection, 
the third combination is the one which closely mimics the setting up of a conventional seeding 
trial where the seed solution is introduced after the protein and precipitant have been mixed 
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(generally at a lower supersaturation which 
favors growth rather than nucleation).  
However, to be thorough we tried all three 
combinations possible.   
The results of the initial seeding trials 
(Figure 38) show that the third combination 
was the most successful one.  Showers of tiny 
crystals were obtained in the first and second 
combination as well, but there were no large, 
isolated crystals nor was there any change in 
crystal morphology when changing the 
dilution of the seed stock solution.  In stark 
contrast, crystals were obtained in the third 
combination and, there was a clear 
differentiation between the crystals between 
different dilution series of the seed solution.  
Figure 38 clearly shows the variation in the 
protein crystals from a shower of tiny crystals 
at low dilution, which is expected as these 
contain a huge number of nuclei, to large, isolated crystals at higher dilutions that contain far 
fewer nuclei to begin with.  The dilution series of 1:10 gave the best crystals in multiple trials, 
consistently producing single, isolated crystals, and were used for all further experiments 
involving PYP.  
5.3.2 On-chip X-ray analysis of PYP crystals grown via microseeding 
Once crystals were obtained, the next step was to ascertain the quality of the crystals grown 
via seeding.  Taking advantage of the fact that the array chips allow for on-chip data collection, 
the chips were taken to LS-CAT for diffraction data collection.  A similar strategy to what was 
used earlier for the case of PhnA was used for data collection.  Multiple chips were setup with 
identical 1:10 dilution of the seeds in all chambers thus allowing for a large number of crystals of 
similar morphology to be grown on a single chip.  The chips were mounted on the beamline as 
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described in the earlier chapters, and wedges of data were 
collected from each of the crystals at room temperature.  
Table 6lists the important crystallographic parameters 
from the diffraction data collected.  The maximum 
resolution diffraction spots obtained from a PYP crystal 
was 1.19 Å, indicative of the high quality of the crystals 
obtained, while the final structure was solved to 1.32 Å.  
Figure 39 shows on-chip diffraction data obtained at 
room temperature from a PYP crystal with the inset 
showing the high quality of the diffraction spots and good 
signal-to-noise of the diffraction data.  The main purpose 
of crystallizing PYP was to use it as a model system for carrying out time-resolved studies using 
a microfluidic platform.  Therefore, the data of PYP collected on the monochromatic beamline 
was not analyzed to full extent in terms of excluding frames to bring down the mosaicity, but it 
was still comparable to previously collected on-chip data.  Integration, merging and scaling of 
the X-ray data was done using HKL 2000 (HKL Research)
38
.  Subsequent processing of the data 
was done using the CCP4 crystallography suite
39
 as described in earlier chapters.  Molecular 
replacement for PYP was done using the 1OTA
40
 structure from the RSCB Protein Data Bank.  
The final model (Figure 40) was made using ARP/wARP
39
.   
Table 6. Summary of crystallographic statistics for PYP crystals grown on-chip 
Parameter PYP data[a] 
Data Collection 
Unit Cell Dimensions a = b = 66.76 Å c = 40.89 Å 
Space Group P63 
Total Observations  
Unique Observations 
804,824  
24,364 
Resolution 50 Å – 1.32 Å 
Rsym 0.111 (0.508) 
Mosaicity 0.02 – 0.54o 
Redundancy 7.9 (6.7) 
Completeness 99.9% (98.4%) 
I/σ 11.1 (2.3) 
Refinement 
R(Rfree) 0.3228 (0.372) 
[a] Reported values are for all hkls.  Values shown in parenthesis represent the value for the highest resolution shell except where indicated.   
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5.4 Conclusions 
We have successfully demonstrated the ability to use the microfluidic array chips to optimize 
crystallization of photoactive yellow protein (PYP) by screening for the optimal microseed 
dilution necessary to seed and obtain a single crystal in each crystallization chamber.  In our lab, 
we have also had initial success in screening for crystallization of succinate quinone reductase 
(SQR) from C. maquilingensis and cytochrome c oxidase.  The current chips are designed to 
screen for crystallization conditions using a two-component approach: the protein being 
crystallized and the precipitant being screened.  In future, the chip design can be altered to 
include a third chamber for the microseed solution, giving greater control over the crystallization 
trial.  In addition, we will incorporate on-chip serial dilution to enable efficient, reproducible 
microseed matrix screening.  It is estimated that the optimized chip will consume 5-20 nL 
protein, 10 nL microseed solution and 5-20 nL precipitant per crystallization well, in a design 
where the protein : precipitant ratio is varied for each precipitant.  Upon optimization of 
crystallization conditions, X-ray data collection can be completed without manual handling of 
the crystals as demonstrated for the array based chips.  We plan to use new 3-compartment chip 
designs for crystallization of membrane proteins of the heme-copper oxidase superfamily and the 
membrane associated members of the electron-transport chain.   
Seeding is a powerful tool to optimize the chances of obtaining high quality crystals of 
targets that do not yield results with conventional methods.  With the array based chip we have 
implemented microseeding on a target protein (PYP), which does not crystallize using standard 
crystallography methods.  The fine control over mixing that microfluidics provides, can allow for 
precise mixing of the seed solution with the protein and precipitant at a given time, thus making 
it easier to control the time and duration of seeding.  These give our chips added advantage in 
terms of flexibility and optimization, making it a better platform for seeding and crystallization.  
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Chapter 6 
Microfluidic approaches for time resolved studies of proteins 
6.1 Introduction  
While in situ diffraction analysis of protein crystals grown in microfluidic devices has been 
reported on previously, these efforts have been focused on the more mainstream approach of 
monochromatic X-ray diffraction.  However, these studies produce only a static picture of the 
protein structure and may be affected by structural artifacts resulting from data collection at 
cryogenic temperatures.  Laue crystallography, takes advantage of polychromatic X-rays, 
frequently performed at room temperature, to increase the rate of data collection and thereby 
facilitate dynamic structural and functional studies.  However, these methods are very sensitive 
to crystal quality and are even more damaging to the crystal than monochromatic X-ray 
diffraction.  X-ray compatible microfluidic crystallization platforms can be used to generate a 
large number of high quality crystals which can be analyzed in situ without the need for manual 
handling.  These capabilities facilitate the analysis of many crystals in order to overcome 
difficulties associated with the severe radiation damage typical of Laue methods.  This chapter 
presents a method for coupling these microfluidic crystallization platforms with automated 
procedures for crystal centering, data collection, and the subsequent analysis of polychromatic 
data taken from many crystals to minimize the effects of radiation damage on the resultant data.  
As proof-of-concept, single polychromatic diffraction images from multiple lysozyme and PhnA 
crystals grown on-chip were collected and merged into a single dataset.  Following this, laser 
mediated on-chip studies of the photo cycle of photoactive yellow protein (PYP) were carried 
out, being the first instance of on-chip time resolved studies. 
X-ray diffraction studies of biomolecules over the last few decades have resulted in a wealth 
of information about three dimensional, static structures of proteins, DNA and RNA molecules.  
These have provided significant insights into the structure and function of these molecules.  
However, a precise understanding of how a protein functions requires not only its three 
dimensional static structure, but also the subtle conformational changes that takes place during 
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protein function
1
.  Therefore to fully understand how these biomolecules function, it is necessary 
to watch them function in real time, along a reaction path that often times involve short-lived 
reaction intermediates.  Many such reactions are possible in crystals as they typically contain a 
large percentage of solvent.  The solvent forms channels and hydration shells around protein 
molecules and facilitates dynamic processes such as diffusion and binding of substrates and other 
ligands, turn-over in enzyme crystals, and conformational change in response to absorption of 
light in photoreceptors
2
. Time resolved X-ray crystallography (TRX) is a unique tool that 
facilitates the study of these structural intermediates allowing the real time investigation of 
structural changes that molecules undergo while performing their function.  TRX can, therefore, 
play an important role in visualizing structures of reaction intermediates thereby elucidating 
reaction mechanism
2
.   
TRX is a term used in a broad sense to describe methods that are used to study the structure 
of intermediates that a macromolecule goes through during a chemical reaction.  These 
approaches can be divided into two main classes, in the first case; the lifetime of the intermediate 
to be studied is artificially extended to match the typical X-ray data collection time available 
from monochromatic synchrotron sources.  This is accomplished by generating a steady state 
accumulation of the intermediate in question by continuous reaction triggering, or by physical 
trapping of the intermediate using fine cryo-temperature control
1,3-5
.  Trapping methods extend 
either the lifetime of the intermediate or increase their concentration, thus making it amenable to 
probe these structures using monochromatic radiation.  Although trapping methods provide 
valuable insight into structures of intermediates, they at the same time perturb the reaction 
they are probing, thus making it necessary to consider the artifacts which these methods 
may have induced.  In stark contrast, under the second approach, instead of extending the 
lifetime of the intermediate, the X-ray exposure time is matched to the lifetime of the  
 114 
 
intermediates. This approach allows us to observe the reaction in its natural state, without any 
external perturbations that might have side effects to the changes we have to be considered. This 
approach is based on employing Laue crystallography, where X-ray diffraction data is obtained 
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by exposing a static crystal to a polychromatic X-ray beam (“pink” beam) at room temperature, 
contrary to the standard X-ray crystallographic set-up where a cryo-cooled, rotating protein 
crystal is exposed to a monochromatic beam
6
.   In this way, exposure times are shortened by 
three to four orders of magnitude relative to monochromatic experiments, opening access to the 
microsecond time domain at which most reactions occur.  A microsecond is about the time it 
takes for an electron bucket to circulate around a synchrotron ring, thus making it possible to 
take advantage of the time-structure of synchrotron radiation to further reduce the effective X-
ray exposure time: if the full synchrotron current is loaded into a single electron bundle, each 
100 ps X-ray pulse generated by this bundle becomes sufficient to provide an interpretable X-ray 
diffraction pattern
1
.  Thus Laue crystallography is a more direct, yet more challenging method to 
study reaction intermediates and understand biomolecule function as it evolves at room 
temperature.  This chapter focuses on Laue crystallography as a method to better understand 
protein function. 
In TRX experiments, supplying the trigger for a chemical reaction to occur is a key step to 
probe structural changes in proteins.  The reaction being studied is triggered in the crystal and X-
rays are used to probe the structural changes at various time delays after the start of the reaction.  
The time resolution is determined by either by the duration of triggering process or the X-ray 
probe pulse, whichever is longer.  Ideally, the trigger should be applied in a time resolution 
which is much smaller than the time of the X-ray pulse and the lifetime of the intermediate.  A 
very high X-ray flux is needed to obtain diffraction data of sub-nanosecond resolution, which is 
possible at the latest X-ray synchrotron facilities (Advanced Photon Source (APS) USA, 
European Synchrotron Radiation Facility (ESRF) France, and Spring 8 (Japan))
2
.  It is 
impossible to record the integral intensity of reflection in such short exposure times using 
monochromatic X-rays, polychromatic X-rays are needed in such cases.  It is ideal if the reaction 
being studied is reversible and the system restores to the original state after a short period of 
time, thus allowing complete data collection from a single crystal.  If the reaction is irreversible, 
the data needs to be collected from a new crystal each time. 
There are many challenges associated with Laue crystallography.  The sub-microsecond time 
resolution comes at a price – the pink, polychromatic X-ray beam is extremely intense, and 
causes excessive radiation damage to protein crystals and is susceptible to induce unwanted 
reactions and chemistries in biomolecules.  Since most of Laue data collection is done at room 
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temperature radiation damage is even more severe and a big issue.  The major reason why Laue 
studies are done at room temperature is because in most cases, the experiment of interest is 
observing a chemical reaction or structural change at biologically relevant temperatures.  
Cryocooling in monochromatic X-ray data collection is used for reducing radiation damage, but 
if used in Laue data collection it has the potential to freeze out potential protein dynamics which 
may be of interest as well as inducing artifacts in the crystal structure that affect the quality of 
data collected.   
The second major issue is that of simultaneous triggering of all the molecules in the protein 
crystal, to ensure that the majority of the molecules are activated and follow the same reaction 
path in a synchronous manner.  When conducted at the sub-nanosecond level, Laue experiments 
are also affected by low signal-to-noise, because short exposure times mean fewer available X-
ray photons, and small exposure times result in small structural changes which are hard to detect.  
This is directly linked to the difficulty in data analysis of Laue diffraction data.  Laue data is also 
extremely sensitive to the quality of the protein crystal, a property measured by the mosaicity of 
the crystal as well by substantial background scattering generated by the polychromatic 
radiation.   
The sensitivity of Laue crystallography to crystal quality, and in particular mosaicity is the 
result of spot elongation during data collection.  During data analysis it is necessary to identify 
the exact location of the various diffraction spots observed.  However, with an elongated or 
streaky spot identification of the spot location is much more difficult.  This problem can be 
further compounded by high levels of background scatter which decrease the signal-to-noise 
ratio for weak spots.  These limitations have typically restricted Laue data collection to crystals 
of relatively high quality and provided an opportunity for a disruptive innovation in this field. 
Efforts in microfluidics for protein crystallization have advanced dramatically in the past ten 
years including a variety of strategies for performing in situ X-ray crystallographic analysis of 
crystals grown on-chip, however the efforts thus far have been limited to the use of 
monochromatic X-ray diffraction studies. Monochromatic X-ray diffraction is used for the vast 
majority of structural biology studies, but these results are limited to a static analysis of the 
protein structure and may be affected by structural artifacts resulting from data collection at 
cryogenic temperatures.  Laue or time resolved crystallography relies on exposing a single 
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stationary crystal to a polychromatic X-ray beam, contrary to monochromatic methods where a 
monochromatic beam of X-rays is shot at a rotating crystal
1
.  Exposure times in Laue are three to 
four orders of magnitude shorter than traditional methods, providing access to microsecond time 
domains in third generation synchrotron sources.  This allows us to probe the structures of 
intermediates while a protein is undergoing structural changes.  Microfluidic platforms have 
immense potential in Laue crystallography because they can address many of the challenges in 
the field today.   
The array chips described in previous chapters have fine control over transport at the 
microscale and can be used to generate a large number of isomorphic crystals in each trial.  This 
allows for data collection from multiple crystals simultaneously, thereby reducing radiation 
damage, without having to mount each crystal individually thus making the process much more 
user friendly.  Using microfluidic platforms it is also probe reactions which are irreversible much 
more easily as multiple crystals can be analyzed in a stress-free manner.  I have already 
demonstrated that the data collected from crystals grown on microfluidic array chips have an 
order of magnitude less mosaicity than traditionally grown crystals, which make it a suitable 
candidate for Laue experiments. 
6.2 Materials and methods  
6.2.1 Device fabrication and operation 
24-well and 96-well array chips (Figure 41a) used here were fabricated and filled as 
described previously
7
.  Briefly, microfluidic chips were fabricated by bonding a thin 
polydimethylsiloxane (PDMS, General Electric RTV 650) fluid layer with either 25 or 50 µm 
features covered with a membrane thickness of ~20 µm.  This fluid layer was chemically bonded 
to a molded cyclic olefin copolymer (COC, 2 mil, 4 mil, 5013 and 6013, from TOPAS Advanced 
Polymers Inc.) control layer and a flat COC substrate.   
6.2.2 Protein and precipitant solutions 
Hen egg white lysozyme (Sigma) was dissolved in 50 mM sodium acetate (Sigma-Aldrich) at 
pH 4.6 with 20% (w/v) glycerol (Fisher Scientific) at a concentration of either 88 mg/mL for 
simple large well experiments or 120 mg/mL for 96-well array chip experiments.  Lysozyme 
concentrations were determined by UV absorbance measurements (Lambda 650 UV-Vis 
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spectrophotometer, Perkin Elmer) at 280 nm using an extinction coefficient of 2.64 mL/(mg-
cm)
8
.  A precipitant solution of 1M NaCl (Aldrich) in 50 mM sodium acetate, pH 4.6 with 20% 
(w/v) glycerol was prepared.  Prior to setting up a crystallization experiment, protein solutions 
were filtered through 0.1 µm (Ultrafree-MC, Millipore) filters.  Precipitant solutions were 
filtered through 0.22 µm (Steriflip, Millipore) filters.   
Selenomethionine labeled PhnA from Sinorhizobium meliloti was dissolved in 20 mM 
HEPES, pH 7.5, at a concentration of 20mg/mL.  From screening experiments with the 96 
condition Hampton Index Screen (Hampton Research), the condition I-80 (0.2M ammonium 
acetate, 0.1M HEPES pH 7.5 and 25% (w/v) PEG 3350) worked best was used for all further 
crystallization trials. The crystallization trials were set up with the protein solution at 1:1 v/v 
ratio and were incubated at 9°C.  
Photoactive yellow protein (PYP) from E. Halophila was expressed as an exogenous product 
in E. Coli and then purified to give holo-PYP that was used for crystallization trials.  Vapor 
diffusion (hanging drop) trials were set up for crystallizing PYP (for obtaining seeds), the 
precipitant used was 2.8M ammonium sulfate and 0.9M sodium chloride at pH 7.0
9
.  Seedstock 
solution was prepared as described in Chapter 5 and the same crystallization condition was used 
to setup trials in the array chips.  A dilution of 1:10 of the seedstock solution was used in all 
cases.  The chips were incubated at room temperature. 
6.2.3 Crystallization experiments 
Crystallization experiments were set up and visualized using either a stereomicroscope 
(Leica, MZ12.5) with an attached digital camera (Leica, DFC295) operated using Leica 
Application Suite software or a computer controlled imaging system comprised of an optical 
microscope (Leica Z16 APO) equipped with an auto-zoom lens (Leica 10447176), a digital 
camera (Leica DFC280), and a motorized x-y stage (Semprex KL66) controlled by Image Pro 
Plus (Media Cybernetics).  For visualization of protein crystals, images were occasionally taken 
with the use of cross-polarizers.   
Filling and operation of the microfluidic devices (Figure 41a) was achieved by the use of 
actuate-to-open valves
10,11
.  A small vacuum pump (Gast) connected to the device through a 
plastic gas manifold (Cole-Parmer Instrument Co.) and 24 AWG PTFE tubing coupled with a 
thin metal tube.  Fluids (protein and precipitant solutions) were supplied to the device by  
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pipetting 1 – 5 µL of solution onto the inlet hole.  Vacuum within the chip from actuation of  
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valves then pulled fluid into the chambers.  After filling, the inlet holes for both the fluid and 
control layers were sealed with Crystal Clear tape (Hampton Research).   
6.2.4 X-ray diffraction experiments 
Diffraction experiments were carried out at beamline 14-ID-B at the Advanced Photon 
Source at Argonne National Laboratories with the assistance of the BioCARS team.
12
  14-ID-B 
is an insertion device station with two in-line undulators (U27 and U23) that can operate over a 
wide energy range of 7 keV to 20 keV (1.77 Å to 0.62 Å) and can provide both a monochromatic 
and polychromatic X-ray beams.  Data was collected with both undulators set to a peak energy of 
12 keV (1.03 Å).  Experiments were also performed with the energies of the undulators offset by 
2 keV (U27 at 11.8 keV (1.05 Å), U23 at 13.8 keV (0.898 Å), thereby increasing the 
polychromatic range of the exposure and increasing the density of diffraction data obtained per 
image.  A MARCCD-165 detector was used, with optical visualization provided by off-axis 
cameras.   
For the collection of multiple frames from a single crystal, the microfluidic chips were 
mounted using a set-screw into a slit cut in a metal tube.  This tube was then glued to a standard 
magnetic goniometer mount.  X-ray exposures of 1 or 10 pulses of 11 electron bunches each 
were used.  A sample-to-detector distance of 100 mm, 120 mm, or 150 mm was used depending 
on the strength of the diffraction signal observed.  Collection of a complete dataset from a single 
crystal was attempted.  90° of data was collected using either a single pass method in steps of 8°, 
or in a gap filling mode in steps of 6°.  All data collection was performed at room temperature. 
For the collection of single-shot data, a 96-well array chip was mounted in a plastic frame 
attached to an automated x-y-z translational stage (Eastern Air Devices) (Figure 42b).  An 
automated python script coupled with two off-axis viewing cameras was used to identify and 
mark the location of individual crystals within the array chip (Figure 42c).  Once identified, 
single-shot data collection on each crystal occurred in an automated fashion.  X-ray exposures of 
10 pulses of 11 electron bunches were used.  A sample-to-detector distance of 110 mm was used.  
All data collection was performed at room temperature. 
Collection of time resolved data on PYP involved shooting the crystal with a laser pulse, 
before striking it with the polychromatic X-ray beam at fixed time intervals to study the 
photocycle.  Sample to detector distance was maintained at 150mm.  Wavelength used was 1.02 
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– 1.16 Å (undulators peaked at 12keV).  A nanosecond laser at 485 nm with a spot size of 
approximately 215 microns ad density of 4.8 mJ/mm
2 
was used, with the duration of a single 
pulse being 7 nanoseconds.  A dark image was recorded initially, then after the laser had been 
shined images were recorded at 500 nanoseconds, 2 microseconds and 1 millisecond.   
At the time of performing the time resolved data collection, the synchrotron was operating in 
the standard 11 bunch mode (1 pulse of X-rays contains 11 bunches).  The time for an entire 11 
bunch pulse to go through is about 1.5us, which was too slow for our purposes.  For static data 
collection we had found that 10 or so 11 bunch pulses gave great signal to noise.  However, since 
we needed faster time resolution we isolated a single bunch out of the pulse-train and then 
accumulated 80 or so laser pulse/probe sequences to generate a single frame of data.  While we 
only needed to do this accumulation strategy for the two fastest time points, it was easier to just 
keep doing it this way for all of our data, rather than switching back and forth from single bunch 
to a complete pulse-train. 
The samples were mounted directly on the goniometer using the standard pin mount.  We 
aligned the sample at 30 degrees, straight-on with the high resolution camera.  We tried to do 
automated rotation for data collection from 20-70 degrees but had trouble with the sample going 
out of the beam.  Instead, we aligned and tested at each point.  Data was collected in 5 degree 
increments from 20-70, but typically only 20-35 ended up being used in the data refinement. 
6.2.5 Analysis of X-ray diffraction data 
Analysis of Laue X-ray diffraction data was performed using Precognition analysis software 
and Epinorm for indexing, geometric refinement, integration, and scaling (Renz Research Inc.).
13
  
C-shell scripting was used to automate the analysis of single-shot diffraction data from multiple 
crystals.  The resolution range for the data was established based on the level at which the 
completeness in the highest resolution shell fell below 25%.  Subsequent processing of 
crystallography datasets was done using the CCP4 suite of programs
14
.  Electron density maps 
were displayed using COOT
15
.  Molecular replacement
16
 for lysozyme was done using PDB 
structure 193L as a model
17
.  All images were indexed and refined separately before merging. 
The resulting .hkl file was converted to .mtz format using f2mtz (CCP4).  Data refinement was 
done using Phenix.refine (PDB structure 3SZY for PhnA).  Simulated annealing was used to 
improve map quality. 
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6.3 Results and discussion 
6.3.1 Microfluidic platforms for Laue crystallography 
Time resolved or Laue crystallography is extremely sensitive to crystal quality, and to ensure 
the clear capture of a protein molecule in motion it is essential that high quality diffraction data 
be collected.  It is also not always possible to collect all the data from a single protein crystal 
because of reaction limitation discussed previously, and hence it may be required to loop and 
mount hundreds of crystals in order to collect a complete dataset.  Since we are interested in 
looking at the protein function at biologically relevant temperatures, Laue crystallography is 
more often than not carried out at room temperature. 
A combination of the above factors make the microfluidic array chips described in previous 
chapters a promising alternative to collect time resolved data.  We have demonstrated the ability 
to grow a large number of isomorphous crystals on-chip and have collected high quality 
diffraction data to solve protein structures.  The mosaicity of crystals grown on-chip is an order 
of magnitude lower than conventionally grown crystals, a further indicator of high quality 
crystals.  Since we can collect wedges of data from multiple crystals, in effect each crystal is 
only exposed to the radiation for a short amount of time, thus allowing for room temperature data 
collection.  The major concern remains whether the signal-to-noise resulting from the 
background scatter of the chip material and the signal from the relatively smaller crystals 
hampers on-chip Laue data collection. 
To assess the effects of radiation damage and background scatter for polychromatic Laue 
data collection we first grew lysozyme crystals in the microfluidic chip.  We then tested different 
data acquisition strategies in an attempt to collect complete single-crystal Laue datasets in situ.  
Data was first collected in a gap-filling mode at 6° increments with the energy of the X-ray beam 
peaked at 12 keV.  While high quality diffraction spots were observed initially (Figure 43a), the 
effects of radiation damage on the relatively small 25 µm thick crystal used in this experiment 
were severe, quickly resulting in poor quality data as evidenced (evident) by the streaky spots 
and the loss of higher resolution diffraction spots (Figure 43b).  Of the 31 diffraction images 
originally intended to comprise the complete dataset, only the first 7 proved to be usable for 
subsequent data analysis, resulting in an incomplete dataset.  
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An alternate data collection strategy was also tried.  Data was also collected with the energy 
of the two undulators offset by 2 keV (11.8 keV (1.05 Å) and 13.8 keV (0.898 Å)).  This offset 
resulted in an X-ray beam with a wider range of energies and thus a higher density of diffraction 
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spots per image.  As the previous attempt at data collection indicated that the lifetime of the 
crystal was not long enough to take advantage of the gap-filling data collection strategy we used 
simple data collection with a larger increment of 8° to try and cover a larger range of diffraction 
space.  Again, high quality diffraction was observed initially (Figure 43c), but radiation damage 
allowed for the analysis of only 9 of the 12 frames collected.  However, the higher density of 
data per frame obtained from using the offset undulators resulted in a higher overall 
completeness of the dataset and an improvement in the resolution.  
While the level of background scatter for the microfluidic chip architecture used in these 
experiments had been tested previously for monochromatic data collection,
7
 the use of a pink X-
ray beam had the potential to increase the level of background scatter above that observed 
previously.  The size of crystals is limited by the height of the microfluidic chamber, resulting in 
a path length through the crystal of ~25 µm for the chips used here.  This path length is relatively 
short in comparison to the ~145 µm path length of the beam through the device materials for 
devices fabricated from 2 mil 5013 COC (total thickness includes ~ 20 µm of PDMS. 
Background scatter from the device materials can be clearly seen as a diffuse ring in the lower 
resolution shells of the diffraction images.  However, the intensity of this scatter did not occlude 
the clear observation of subsequent diffraction spots.  While this ratio of the diffraction path 
through the crystal compared to background through the device proved to be adequate for the 
strongly diffracting crystals of lysozyme used in these experiments a longer path length through 
the crystal would facilitate the analysis of more weakly diffracting crystals.  To test this, we 
conducted single shot Laue data collection on crystals of PhnA as well.  These crystals were not 
as robust as Lysozyme so would be a better test if the chip could be used to collect useful data.  
To ensure the path length of the X-ray through the crystal was maximized, we switched to a 
much thinner substrate made out of Duralar.  The fluid layer that houses the crystallization 
chambers were made taller (60 µm instead of 25 µm) allowing the crystal more space to grow, 
thus increasing the path length of the X-ray traversed through the crystal in comparison to the 
chip materials. 
Due to the significant radiation damage resulting (Figure 43d) from the exposure of a crystal 
to a polychromatic X-ray beam at room temperature; it was difficult to obtain a complete high 
quality diffraction dataset from a single small crystal.  Considering that the model system 
lysozyme forms robust and strong crystals, this issue would be further exacerbated in other  
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protein targets.  The radiation damage and increases in crystal mosaicity that we observe here 
would be expected to be much more significant for crystals of most other proteins.  However, our 
approach has the advantage of being able to produce a large number of crystals in the array chip.  
Therefore a large array chip with 96 wells was used to generate a large number of lysozyme and 
PhnA crystals, enabling "single-shot" structure determination.  In the optimized devices the 
crystals were able to grow to ~50 µm in size and did not appear to have been significantly 
limited in their growth by the height of the chamber.   
Data collection via a single shot of large number of crystals is particularly attractive for 
microfluidic applications, provided that crystals can be grown in random orientation on-chip.  
One of the significant challenges for data collection in a planar microfluidic device is the need to 
maintain alignment of the crystal during rotation, coupled with geometric limitations for rotation 
of the device.  For single-shot analysis the microfluidic chip can be mounted perpendicular to the 
X-ray beam and simply translated from well-to-well.  The random orientation of crystals within 
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the chip would then allow for a full survey of rotational space without having to rotate the 
sample itself.  This type of a setup avoids difficulties with rotational and geometric limitations 
and eases difficulties with optically aligning a rotating crystal in the beam.  This method was 
further enabled by the development of an automated method described in Section 6.3.2 for 
marking the location of crystals within a microfluidic chip such that data collection could be 
performed automatically once crystals have been identified.   
6.3.2 Automated data collection strategy at BioCARS 
The planar nature and large size of the microfluidic chips make it difficult to center each 
crystal individually and therefore single shot data collection from randomly oriented crystals in 
each well is a well-suited approach.  As discussed before, single-shot data collection from 
multiple crystals on a single chip also makes it easier for collecting time resolved data because 
the radiation damage can be negated to a great extent as a single crystal is not subjected to 
radiation for an extended time.  The 96-well array chips however can have close to three to four 
hundred crystals and collecting data from each of the crystals one at a time, and then translating 
over to the next one can be laborious.  Dr. Zhong Ren at BioCARS has developed an automated 
x-y-z stage that is motor controlled and coupled to software running on the X-ray data collection 
computer.  How this software coupled to the motor works is as follows.  The array chip is 
mounted in the beam (Figure 42), and the crystals can be identified with the help of two high 
resolution cameras mounted on the beamline.  The software allows us to mark each crystal 
position, translate the chip to the next well (or same well if there are multiple crystals) and 
sequentially mark all the crystals grown on the chip.  The accuracy of the program is such that it 
can successfully target crystals that are close together in a single well.  The program stores the 
location of all the crystals thus marked.  There is also a provision to record detector distance and 
exposure time for each crystal.  When all crystals have been identified and marked, the program 
sequentially shoots each crystal according to the data stored, and automatically completes data 
collection from all the crystals on the chip. 
The automated stage, along with the accompanying software makes data collection from a 
large number of crystals very straightforward.  Data collection for Lysozyme and PhnA was 
performed using this method.  Also, the accuracy of crystal marking coupled with fine control of 
sample translation over the entire dimensions of the chip (20 mm x 10 mm) were validated in  
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that only a single frame of data was collected which showed overlapping diffraction patterns 
from multiple crystals, despite the close proximity of many crystals within wells.  For PYP a 
different approach was used since the reaction that was being captured had to be triggered using 
a laser pulse prior to shooting the crystal with X-rays and wedges of data needed to be collected 
from each crystal so single shot data collection would not work.  The sample was therefore 
mounted on the goniometer (similar to the monochromatic data collection) and data was 
collected from each crystal manually.  The time delay between these two events was controlled 
to 500 nanoseconds, 2 microseconds and 1 millisecond on different crystals so the entire reaction 
pathway could be studied. 
6.3.3 On-chip single shot and time resolved crystallography  
Table 7 shows the important crystallographic statistics from single-shot Laue data collection 
on lysozyme and PhnA. In comparison to monochromatic data collection, we see that the 
resolution and completeness are not as good, which is due to the fact that radiation damage is 
much stronger for polychromatic data collection.  However, for Laue data collection what is 
observed is that data obtained from merging wedges from multiple crystals at room temperature 
is superior to data obtained from a similar sized single crystal on-chip.  This is due to minimizing 
the effects of radiation damage by merging of datasets.  In addition to obtaining a more complete 
dataset, merging also gave data to a far better resolution than that obtained using a single crystal.   
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Table 7. Summary of crystallographic statistics for lysozyme and PhnA crystals grown 
on-chip 
Parameter Lysozyme PhnA 
Data Collection 
Unit Cell 
Dimensions 
a = b = 113.19Å c = 73.87Å a = b = 113.232Å c = 74.261Å 
Space Group P43212 P43212 
Resolution 100Å – 1.61Å 100Å – 2.06Å 
Rmerge on |F| 0.060 0.082 
Rmerge on |F|
2 0.095 0.131 
Completeness 87.47% (30.00%) 90.33% (36.29%) 
Mean F/σ(F) 43.06 (18.80) 35.14 (13.26) 
# of Frames 67 115 
Refinement 
R (Rfree) 0.187 (0.253) 0.282 (0.381) 
Ramachandran Statistics 
Most Favored 97.6% (124) 93.1% (377) 
Allowed 2.4% (3) 4.9% (20) 
Disallowed 0.0% (0) 2.0% (8) 
Reported values are for all hkls.  Values shown in parenthesis represent the value for the highest 
resolution shell except where indicated.  For the Ramachandran statistics the number in parenthesis 
indicates the number of residues in a given region.   
R-factor = Σ (|Fobs|-k|Fcalc|)/Σ |Fobs|and Rfree is the R value for a test set of reflections consisting of a 
random 5% of the diffraction data not used in refinement.   
Rsym = Σ |(Ii - <Ii> | Σ Ii where Ii = intensity of the i
th reflection and <Ii> = mean intensity. 
 
Figure 44 shows the electron density map of lysozyme obtained by merging data from 
multiple crystals using (a) polychromatic and (b) monochromatic diffraction.  While it is clear 
that the monochromatic data is much more complete and of higher quality, for proof-of-
principle, merging datasets using polychromatic diffraction provides acceptable structural 
information.  Figure 45 shows the electron density map for PhnA obtained from single-shot 
diffraction and merging datasets from multiple crystals.   
Preliminary crystallographic data from time resolved studies of PYP are shown in Table 8.  
From the resolution values and completeness, it is evident that the data is of good quality and 
that we were able to collect diffraction data on each of the time points.  The R-values are 
comparatively high because the space group P63 can be indexed in two ways.  In preliminary 
data analysis, we merged the data from crystals indexed in two different ways.  This error is 
being fixed and more stringent parameters and optimization is being applied to the indexing and 
refining of data, which has brought down the R-values from 0.08(0.13) to a more acceptable 
0.03(0.05) (Data analysis in progress, not shown).  
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Table 8. Summary of time-resolved crystallographic statistics for PYP crystals grown on-chip 
Parameter Dark 1 500 ns 2 us 1 ms Dark 2 
Data Collection 
Resolution 100Å – 1.82Å 100Å – 1.84Å 100Å – 1.80Å 100Å – 1.80Å 100Å – 1.78Å 
Rmerge on |F| 0.083 0.078 0.087 0.082 0.075 
Rmerge on |F|
2 0.136 0.124 0.141 0.134 0.118 
Completeness 94.9% (87.6%) 86.1% (67.6%) 86.3% (64.9%) 88.0% (64.5%) 89.9% (71.2%) 
Mean F/σ(F)  25.3 (15.4)  24.3 (11.1) 23.2 (9.1) 24.0 (18.1) 25.8 (12.3) 
# of Frames 36 24 25 29 29 
Space group: P63. Unit cell dimensions: a = b = 66.76Å c = 40.893Å. Reported values are for all hkls.  Values shown in parenthesis represent 
the value for the highest resolution shell except where indicated. 
6.4 Conclusions 
Time-resolved crystallography therefore has a distinct advantage as it provides direct and 
structural information, for the entire molecule, in atomic detail as a function of time.  As such, it 
is ideally suited for following the propagation of structural changes throughout the protein from 
the active site (heme in heme proteins, for example), for exploring the events involved in an 
allosteric mechanism and for tracking the ligands on their migration pathways throughout a 
protein.  However, difficulties associated with data collection at biologically relevant 
temperatures, extremely high radiation damage from the polychromatic beam, and difficulty in 
sample preparation, mounting and data analysis have slowed down the widespread acceptance of 
this method.  There is a strong case for using microfluidics to address some of these challenges. 
The potential of using microfluidic platforms for protein crystallization with on-chip X-ray 
analysis capabilities has been demonstrated for polychromatic Laue diffraction methods.  The 
effects of sample and device geometry have been investigated and an automated "single-shot" 
method for obtaining a complete dataset from many crystals grown on-chip has been developed 
in collaboration with the BioCARS team at the Advanced Photon Source at Argonne National 
Laboratory.  Further, collection of on-chip time resolved data on PYP has also been 
demonstrated strengthening the case for using microfluidics for performing functional studies on 
protein targets. 
While the proof-of-concept experiments performed here have merely validated the approach, 
the application of microfluidic crystallization platforms with on-chip diffraction analysis 
capabilities for Laue crystallography has tremendous potential for further development.  The 
majority of Laue experiments investigate time resolved structural changes, but have been limited 
thus far to systems for which robust protein crystals can be grown.  Eliminating the need for 
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manual handling of crystals not only avoids the potential for physically damaging fragile 
crystals, it also enables the analysis of a significantly larger number of crystals.  Further, 
microfluidics has the advantage of having precise control over transport at the microscale that 
can be used to trigger reactions in proteins by addition of a ligand, or by changing the pH or 
temperature.  The further development and validation of this technology for time resolved and 
dynamic crystallography studies would be extremely powerful.   
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Chapter 7 
Concluding remarks and future work 
7.1 Summary 
In the course of my Ph.D. work, I have developed a microfluidic platform that serves to 
address some of the major bottlenecks faced by the protein crystallization and structure 
determination community.  The first advantage of using the microfluidic platform is the ease of 
screening tens of thousands of crystallization conditions using a fraction of the protein solution 
needed in conventional methods.  Secondly, the material used in chip fabrication, as well as the 
chip design, is such that it is X-ray transparent allowing on-chip analysis of the protein crystals 
grown.  Further, the ability to optimize and get an initial estimate of crystal quality via on-chip 
X-ray diffraction data collection in the screening phase is an added advantage.  We have also 
demonstrated the ability to collect complete datasets at room temperature by collecting and 
merging wedges of data from multiple crystals.  This allows us to probe the structure and 
function of crystals that are not amenable to cryo-cooling.  Further, the platform
1
 eliminates 
manual harvesting of crystals since it is X-ray transparent, thus allowing the analysis of small 
and/or fragile crystals.  Because we do not handle the crystals or cryo-cool them, the quality of 
data collected (indicated by mosaic spread) is an order of magnitude better than what is seen in 
traditional methods.   
De novo structure determination of PhnA was accomplished by first collecting SAD phase 
information from a SeMet derivative and then using the phase information for structure building 
and obtaining the final 3D structure.  This is the first reported work of on-chip phasing from 
multiple crystals using a microfluidic platform.  Further, I implemented a crystallization 
optimization technique, microseeding on our microfluidic platform.  As proof-of-concept, I took 
PYP, a protein of which it is extremely difficult to grow single large crystals.  We successfully  
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implemented the microseeding technique on-chip and were able to grow and collect data from 
single, isolated crystals.  Finally, our platform has also been utilized for carrying out dynamic 
studies on various proteins.  We have successfully collected time-resolved Laue data from 
protein crystals (PYP) grown on-chip.  Currently we are processing data that will allow us to  
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observe the various steps of the photo-cycle PYP undergoes when it is subject to a laser pulse.  
This will be the first time that a microfluidic platform has been used to study these ultra-fast 
reactions.  What I have developed over the course of my PhD is a multi-faceted microfluidic 
platform capable of not only looking at static structure of various proteins but also investigating 
protein dynamics in the sub-nanosecond scale.  It can be utilized for the complete understanding 
of a protein structure, right from the start where we screen for conditions to get the optimum 
crystallization condition, followed by static structure determination using a monochromatic light 
source, and finally being able to visualize the protein molecule in motion using polychromatic 
Laue diffraction. 
7.2 Future directions 
To further expand the capabilities of the microfluidic crystallization platform our group is 
currently looking at the following different areas for further studies. 
7.2.1 Membrane protein crystallization via bicelles  
Membrane proteins account for nearly a third of all proteins; however they are vastly 
underrepresented in terms of total structures in the protein data bank (www.pdb.org).
2
   Of the 
over 80,000 structures available in the data base, only 1200 are membrane proteins, which 
amounts to about one percent of total structures.  This is because membrane proteins are 
notoriously hard to crystallize primarily due to their amphiphilic nature.  There exist a number of 
methods for crystallizing membrane protein, (a) in surfo (b) in meso (lipidic cubic phase) and (c) 
bicelle based methods.
3
  Of these, the in surfo method is the oldest and is responsible for the 
maximum number of structures.  However this method relies on using detergents to solubilize 
the protein, which often causes denaturing and leads to poor crystal quality.  The type of crystal 
packing associated with this method is also not amenable to giving the best quality of diffraction 
from the crystals.  The in meso and the bicelle based method have been recently developed and 
they both stabilize the protein in a more membrane-like environment, leading to better crystal 
packing and higher quality crystals.  Another graduate student in our group is working to 
implement the in meso method on a microfluidic platform.  I have conducted preliminary 
experiments to show that the bicelle based method can work on the microfluidic platform 
discussed in this dissertation.  Crystals of the membrane protein bacteriorhodopsin have been 
grown via a modified crystallization protocol and on-chip data has been collected to 3.1 Å  
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(Figure 46).  We are in the process of optimizing the crystallization conditions to grow better 
quality crystals and collect enough data for a complete dataset.  
The initial success in implementing the bicelle based method on the existing platform holds 
great promise.  We have access to a number of membrane proteins, which has either not been 
crystallized or whose high resolution structures are not available due to inability to grow large, 
high quality crystals using conventional methods.  Some of these proteins include the ba3, bo3, 
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bd and aa3 type heme-copper oxidases.  Currently efforts are underway to screen these proteins 
using the bicelles with commercially available screens. 
7.2.2 Crystallization of proteins in different space groups 
The proteins discussed in the dissertation all belong to high symmetry space groups, namely 
tetragonal and hexagonal.  These high symmetry space groups mean that relatively lesser number 
of random orientations is needed to get the complete structure.  It would be an interesting study 
to crystallize proteins that crystallize in low symmetry space groups, for e.g., monoclinic or 
triclinic.  This would require data from a much larger number of randomly oriented crystals to 
get a complete dataset.  Ensuring that the microfluidic platform is capable of collecting data from 
these low symmetry based crystals would further strengthen its versatility. 
I have carried out preliminary experiments with lysozyme, to grow crystals in the triclinic 
space group by varying the crystallization conditions.  Lysozyme is known to have difficulty in 
crystallizing in this low symmetry space groups and prefers the tetragonal geometry.  Since the 
chips are X-ray transparent, it is much easier to check on various space groups after crystals have 
been obtained and to verify that the data being collected is indeed from the desired space group.  
Figure 47 shows preliminary results from such lysozyme crystals with excellent diffraction data.  
Analysis of the diffraction data in ongoing, and a full structure of the protein in the triclinic space 
group will be obtained shortly. 
7.2.3 Microseeding efforts for heme-copper oxidases 
 Microseeding
4
 as discussed in Chapter 5 is an optimization method using which the 
nucleation and growth phases of crystallization can be decoupled, leading to the growth of 
single, large crystals.  After having demonstrated that on-chip seeding can be used to grow large, 
well diffracting crystals of PYP, we are currently working on applying this technique to 
crystallize several members of the heme-copper oxidase family (ba3, bd, bo3, aa3) as well as 
quinol reductase (SQR).  We have currently obtained showers of microcrystals from some of 
these targets and are looking to utilize these microcrystals as seed stock for further experiments. 
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